
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Mol. Cancer</journal-id><journal-title-group><journal-title>Molecular Cancer</journal-title></journal-title-group><issn pub-type="epub">1476-4598</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31690319</article-id><article-id pub-id-type="pmc">6833286</article-id><article-id pub-id-type="publisher-id">1091</article-id><article-id pub-id-type="doi">10.1186/s12943-019-1091-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Qin</surname><given-names>Shuang</given-names></name><address><email>617150988@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Linping</given-names></name><address><email>394499805@qq.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yi</surname><given-names>Ming</given-names></name><address><email>1978135000@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Shengnan</given-names></name><address><email>1334870996@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2499-1032</contrib-id><name><surname>Wu</surname><given-names>Kongming</given-names></name><address><phone>13517196182</phone><email>kmwu@tjh.tjmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Luo</surname><given-names>Suxia</given-names></name><address><email>luosxrm@163.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0368 7223</institution-id><institution-id institution-id-type="GRID">grid.33199.31</institution-id><institution>Department of Oncology, Tongji Hospital of Tongji Medical College, </institution><institution>Huazhong University of Science and Technology, </institution></institution-wrap>1095 Jiefang Avenue, Wuhan, 430030 Hubei China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1799 4638</institution-id><institution-id institution-id-type="GRID">grid.414008.9</institution-id><institution>Department of Medical Oncology, </institution><institution>The Affiliated Cancer Hospital of Zhengzhou University &#x00026; Henan Cancer Hospital, </institution></institution-wrap>Zhengzhou, 450008 China </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>18</volume><elocation-id>155</elocation-id><history><date date-type="received"><day>17</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>18</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibodies (mAbs), has shaped therapeutic landscape of some type of cancers. Despite some ICIs have manifested compelling clinical effectiveness in certain tumor types, the majority of patients still showed de novo or adaptive resistance. At present, the overall efficiency of immune checkpoint therapy remains unsatisfactory. Exploring additional immune checkpoint molecules is a hot research topic. Recent studies have identified several new immune checkpoint targets, like lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), T cell immunoglobulin and ITIM domain (TIGIT), V-domain Ig suppressor of T cell activation (VISTA), and so on. The investigations about these molecules have generated promising results in preclinical studies and/or clinical trials. In this review, we discussed the structure and expression of these newly-characterized immune checkpoints molecules, presented the current progress and understanding of them. Moreover, we summarized the clinical data pertinent to these recent immune checkpoint molecules as well as their application prospects.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Immunotherapy</kwd><kwd>Immune checkpoint</kwd><kwd>LAG-3</kwd><kwd>TIM-3</kwd><kwd>TIGIT</kwd><kwd>VISTA</kwd><kwd>B7-H3</kwd><kwd>BTLA</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81572608, 81874120</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Kongming</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100010888</institution-id><institution>Wuhan Municipal Science and Technology Bureau</institution></institution-wrap></funding-source><award-id>2017060201010170</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Kongming</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par39">The past decade has witnessed the rapid development of immunotherapy. Now, it has been recognized as a key strategy to control the progression of malignant tumors. Among these immunotherapies, immune checkpoint inhibitors (ICIs) [<xref ref-type="bibr" rid="CR1">1</xref>], chimeric antigen receptor T cell [<xref ref-type="bibr" rid="CR2">2</xref>] and bispecific antibodies [<xref ref-type="bibr" rid="CR3">3</xref>] are the most promising immunotherapy strategies. Encouragingly, the 2018 Nobel Prize in Physiology and Medicine was awarded to Drs. James Allison and Tasuku Honjo, who discovered programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), to honor their outstanding work for the development of immunotherapy [<xref ref-type="bibr" rid="CR4">4</xref>]. In addition, Dr. Lieping Chen did seminal contributions to the discovery of PD-L1 (CD274, B7-H1) [<xref ref-type="bibr" rid="CR5">5</xref>]. Now, these immune checkpoint targets have realized the transformation from the laboratory to the clinical application.</p><p id="Par40">CTLA-4 is a cell-surface receptor related to CD28, binding to the ligands CD80 (B7&#x02013;1) and CD86 (B7&#x02013;2) [<xref ref-type="bibr" rid="CR6">6</xref>]. The binding of CTLA-4 to CD80/CD86 delivers a negative signal to T cells activation by making CD80/CD86 less available to CD28 [<xref ref-type="bibr" rid="CR7">7</xref>]. In the early 1996, Leach and his colleagues found that injecting anti-CTLA-4 antibody in mice with pre-established tumors significantly reduced tumor growth [<xref ref-type="bibr" rid="CR8">8</xref>]. Ipilimumab, as the first anti-CTLA-4 monoclonal antibody (mAb) reaching the clinic [<xref ref-type="bibr" rid="CR9">9</xref>], garnered the approval for the treatment of patients with malignant melanoma in 2011 [<xref ref-type="bibr" rid="CR10">10</xref>]. PD-1, also known as CD279, belongs to CD28 superfamily [<xref ref-type="bibr" rid="CR11">11</xref>]. The binding of PD-1 to its ligands PD-L1 and PD-L2 (CD273, B7-DC) serves as a &#x0201c;rheostat&#x0201d; of immunological regulation, suppressing the activation and function of T cells to downregulate the immune response [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Pembrolizumab, the first humanized mAb against PD-1, gained its first global approval for patients with unresectable or metastatic melanoma by United States Food and Drug Administration (FDA) in 2014 [<xref ref-type="bibr" rid="CR14">14</xref>]. Subsequently, its indication was expended to head and neck squamous cell carcinoma (HNSCC) [<xref ref-type="bibr" rid="CR15">15</xref>], non-small cell lung cancer (NSCLC) [<xref ref-type="bibr" rid="CR16">16</xref>], metastatic urothelial carcinoma [<xref ref-type="bibr" rid="CR17">17</xref>], cervical carcinoma [<xref ref-type="bibr" rid="CR18">18</xref>] among others in a list that continues to grow. By the end of 2018, as many as 7 types of ICIs have been approved by FDA for the treatment of cancers and all of them were immune checkpoint blockers against PD-1/PD-L1 or CTLA-4 [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par41">Nevertheless, the response rate of anti-PD-1/PD-L1 mAb and anti-CTLA-4 mAb in overall patients is far from satisfactory. Most patients show primary or acquired resistance to these ICIs [<xref ref-type="bibr" rid="CR9">9</xref>]. Thus, intensive researches aimed at finding novel immune checkpoint targets have been ongoing. The next generation immune checkpoints such as lymphocyte activation gene-3 (LAG-3) [<xref ref-type="bibr" rid="CR20">20</xref>], T cell immunoglobulin and mucin-domain containing-3 (TIM-3) [<xref ref-type="bibr" rid="CR21">21</xref>], T cell immunoglobulin and ITIM domain (TIGIT) [<xref ref-type="bibr" rid="CR22">22</xref>], V-domain Ig suppressor of T cell activation (VISTA) [<xref ref-type="bibr" rid="CR23">23</xref>], B7 homolog 3 protein (B7-H3) [<xref ref-type="bibr" rid="CR24">24</xref>] and B and T cell lymphocyte attenuator (BTLA) [<xref ref-type="bibr" rid="CR25">25</xref>] demonstrate as promising therapeutic targets with the chance to realize clinical application. In this review, we will emphasize these newly-characterized immune checkpoint molecules and their clinical studies that suggest the promising future for the clinical application.</p></sec><sec id="Sec2"><title>Immune checkpoints</title><p id="Par42">The full activation of T cell dependents on two different signals, signal one is derived from the interaction between antigenic peptide/major histocompatibility complex (MHC) on the surface of APCs and the T cell receptor (TCR), and signal two requires an antigen-independent co-signaling molecules [<xref ref-type="bibr" rid="CR26">26</xref>]. Note worthily, T cell activation is tightly regulated by co-stimulators or co-inhibitors known as immune checkpoints [<xref ref-type="bibr" rid="CR7">7</xref>]. If antigen/MHC and TCR binding is accompanied by the engagement of costimulatory receptors, such as CD28, it allows T cell to proliferate and to migrate toward specific antigen. On the contrary, if antigen/MHC and TCR binding is accompanied by the engagement of coinhibitory receptors, such as CTLA-4, it will suppress T cell activation [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. CTLA-4 is not detectable in na&#x000ef;ve T cell but is rapidly induced upon T cell activation and it primarily regulates the amplitude of T cell during the early priming phase in lymphoid organs [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. The binding of CTLA-4 to B7 proteins competes CD28 costimulatory signals and eventually acts to impede excessive immunity [<xref ref-type="bibr" rid="CR31">31</xref>]. The aim of this co-inhibitor is to minimize damage to normal tissues and prevent unwanted autoimmunity [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. In contrast to CTLA-4, PD-1 plays a major role in the maintenance of peripheral tolerance [<xref ref-type="bibr" rid="CR33">33</xref>]. The engagement of PD-1 by its ligands results in the recruitment of Src homology 2 (SH2) domain containing phosphatases 1/2 (SHP1/2) and then inhibits T cell proliferation and cytokine secretion mediated by TCR [<xref ref-type="bibr" rid="CR34">34</xref>]. Some cancer cells possess the ability to generate inhibitory ligands which can bind co-inhibitory receptor molecules. This engagement limits normal anti-tumor immune responses thus assisting in immune escape [<xref ref-type="bibr" rid="CR35">35</xref>]. Therefore, the blockades of these immune checkpoints are capable to invoke patient&#x02019;s own anti-tumor immune response [<xref ref-type="bibr" rid="CR32">32</xref>]. Immune checkpoint therapies do not kill cancer cells directly, instead they harness the power of the host&#x02019;s immune system to re-enhance endogenous anti-tumor activity [<xref ref-type="bibr" rid="CR36">36</xref>].</p></sec><sec id="Sec3"><title>Newly emerging immune checkpoints</title><p id="Par43">Apart from CTLA-4 and PD-1, novel immune checkpoint molecules on T cells have been discovered continuously. So far, all these emerging immune checkpoints targets are either in the clinical trial or under active development. Those delineated below are the most promising immune checkpoint targets for which blocking antibodies are available in clinical trials (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). A substantial body of evidence accumulates to indicate the synergistic effect of combinatorial blockade among these new immune checkpoints and anti-PD-1/L1 and/or anti-CTLA-4 mAbs. Huang and his colleague utilized a murine model to explore the effect of combinatorial blockade of LAG-3 and PD-1 pathways in ovarian cancer [<xref ref-type="bibr" rid="CR37">37</xref>]. Their results showed that dual blockade of LAG-3 and PD-1 synergistically enhanced anti-tumor immunity and suppressed tumor growth by enhancing CD8<sup>+</sup> tumor infiltrating T cells (TILs) and decreasing regulatory T cells (Tregs) in the tumor microenvironment (TME) [<xref ref-type="bibr" rid="CR37">37</xref>]. The same group further detected the level of other inhibitory receptors when PD-1 or LAG-3 was blocked. When the mice were treated with anti-PD-1 mAb, the level of LAG-3 and CTLA-4 were increased. Interesting, treatment with anti-LAG-3 mAb upregulated the level of PD-1 [<xref ref-type="bibr" rid="CR38">38</xref>]. Their experiments indicated that the blockade of a single immune checkpoint targets may lead to compensatory upregulation of other checkpoint receptors in TME. The similar compensatory mechanism between TIM-3 and PD-1 was observed in lung cancer [<xref ref-type="bibr" rid="CR39">39</xref>] and melanoma [<xref ref-type="bibr" rid="CR40">40</xref>]. It seems that the compensatory mechanism is common across different types of cancer. These preclinical results pave the way for the combinatorial blockade strategies in clinical trials.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>The clinical trials of novel immune checkpoint inhibitors in cancer immunotherapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Target</th><th>Drugs (company)</th><th>Combination agents</th><th>Phase</th><th>Tumor types</th><th>Clinical Trial NO.</th><th>State</th></tr></thead><tbody><tr><td>LAG-3</td><td>IMP321/Eftilagimod alpha (Immutep)</td><td>&#x02013;</td><td>I</td><td>Metastatic RCC</td><td>NCT00351949</td><td>Completed</td></tr><tr><td/><td/><td>Paclitaxel</td><td>I</td><td>MBC</td><td>NCT00349934</td><td>Completed</td></tr><tr><td/><td/><td><p>Cyclophosphamide, fludarabine,</p><p>Melan-A VLP vaccine</p></td><td>I</td><td>Metastatic melanoma</td><td>NCT00324623</td><td>Completed</td></tr><tr><td/><td/><td>HLA-A2 peptides</td><td>I/II</td><td>Disease-free melanoma</td><td>NCT00365937</td><td>Terminated</td></tr><tr><td/><td/><td>Gemcitabine</td><td>I</td><td>Advanced pancreas cancer</td><td>NCT00732082</td><td>Terminated</td></tr><tr><td/><td/><td>Tumor antigenic peptides, montanide</td><td>I/II</td><td>Advanced melanoma</td><td>NCT01308294</td><td>Terminated</td></tr><tr><td/><td/><td>Paclitaxel</td><td>II</td><td>Metastatic breast cancer</td><td>NCT02614833</td><td>Active, not recruiting</td></tr><tr><td/><td/><td>Pembrolizumab</td><td>I</td><td>Metastatic melanoma</td><td>NCT02676869</td><td>Active, not recruiting</td></tr><tr><td/><td/><td>&#x02013;</td><td/><td>Advanced solid tumors</td><td>NCT03252938</td><td>Recruiting</td></tr><tr><td/><td/><td>Pembrolizumab</td><td>II</td><td>Advanced NSCLC and HNSCC</td><td>NCT03625323</td><td>Recruiting</td></tr><tr><td/><td>Relatlimab /BMS-986016 (BMS)</td><td>Nivolumab</td><td>I/II</td><td>Advanced solid tumors</td><td>NCT01968109</td><td>Recruiting</td></tr><tr><td/><td/><td>Nivolumab</td><td>I</td><td>Advanced solid Tumors</td><td>NCT02966548</td><td>Recruiting</td></tr><tr><td/><td/><td>Nivolumab and Urelumab</td><td>I</td><td>Recurrent glioblastoma</td><td>NCT02658981</td><td>Recruiting</td></tr><tr><td/><td/><td>Nivolumab</td><td>I</td><td>Recurrent glioblastoma</td><td>NCT03493932</td><td>Recruiting</td></tr><tr><td/><td/><td><p>Nivolumab, Carboplatin,</p><p>Paclitaxel, Radiation</p></td><td>I</td><td>Gastro/esophageal cancer</td><td>NCT03044613</td><td>Recruiting</td></tr><tr><td/><td/><td>Nivolumab, Cabiralizumab, Ipilimumab, anti-GITR, IDO1 Inhibitor, Lirilumab, Radiation</td><td>I</td><td>Advanced solid tumors</td><td>NCT03335540</td><td>Recruiting</td></tr><tr><td/><td/><td>Nivolumab, Ipilimumab</td><td>I/II</td><td>Virus-associated tumors</td><td>NCT02488759</td><td>Recruiting</td></tr><tr><td/><td/><td>Nivolumab</td><td>I/II</td><td>Advanced hematologic malignancies</td><td>NCT02061761</td><td>Recruiting</td></tr><tr><td/><td/><td>Nivolumab, Ipilimumab, BMS-986205</td><td>I/II</td><td>Advanced solid tumors</td><td>NCT03459222</td><td>Recruiting</td></tr><tr><td/><td/><td>Nivolumab</td><td>II</td><td>Advanced chordoma</td><td>NCT03623854</td><td>Recruiting</td></tr><tr><td/><td/><td>Nivolumab</td><td>II</td><td>Metastatic melanoma</td><td>NCT03743766</td><td>Recruiting</td></tr><tr><td/><td/><td>Nivolumab</td><td>II</td><td>MSS advanced CRC</td><td>NCT03642067</td><td>Recruiting</td></tr><tr><td/><td/><td>Nivolumab</td><td>II</td><td>MSI-H solid tumors</td><td>NCT03607890</td><td>Recruiting</td></tr><tr><td/><td/><td><p>Nivolumab, Ipilimumab,</p><p>BMS-986205, BMS-813160</p></td><td>II</td><td>Advanced RCC</td><td>NCT02996110</td><td>Recruiting</td></tr><tr><td/><td/><td>Nivolumab, Ipilimumab, BMS-986205</td><td>II</td><td>Advanced GC</td><td>NCT02935634</td><td>Recruiting</td></tr><tr><td/><td/><td><p>Nivolumab, Dasatinib, Ipilimumab,</p><p>BMS- 986205</p></td><td>II</td><td>Advanced NSCLC</td><td>NCT02750514</td><td>Active, not recruiting</td></tr><tr><td/><td/><td>Ipilimumab, Nivolumab, Cobimetinib, Daratumumab, anti-LAG-3 antibody</td><td>II</td><td>Advanced CRC</td><td>NCT02060188</td><td>Active, not recruiting</td></tr><tr><td/><td/><td>Nivolumab, Ipilimumab</td><td>II</td><td>Melanoma</td><td>NCT02519322</td><td>Recruiting</td></tr><tr><td/><td>LAG525 (Novartis)</td><td>PDR001</td><td>I/II</td><td>Advanced solid tumors</td><td>NCT02460224</td><td>Active, not recruiting</td></tr><tr><td/><td/><td><p>PDR001, NIR178, capmatinib,</p><p>MCS110, canakinumab</p></td><td>I</td><td>TNBC</td><td>NCT03742349</td><td>Recruiting</td></tr><tr><td/><td/><td>PDR001</td><td>II</td><td>Advanced solid and hematologic malignancies</td><td>NCT03365791</td><td>Active, not recruiting</td></tr><tr><td/><td/><td>PDR001, carboplatin</td><td>II</td><td>Advanced TNBC</td><td>NCT03499899</td><td>Recruiting</td></tr><tr><td/><td/><td><p>PDR001, capmatinib,</p><p>canakinumab, ribociclib</p></td><td>II</td><td>Advanced melanoma</td><td>NCT03484923</td><td>Recruiting</td></tr><tr><td/><td>MK-4280 (Merck)</td><td>Pembrolizumab, Oxaliplatin, Irinotecan, Leucovorin, 5-FU, MK-4280A</td><td>I</td><td>Advanced solid tumors</td><td>NCT02720068</td><td>Recruiting</td></tr><tr><td/><td/><td>pembrolizumab</td><td>I/II</td><td>Hematological malignancies</td><td>NCT03598608</td><td>Recruiting</td></tr><tr><td/><td/><td>Pembrolizumab, Lenvatinib, MK-1308</td><td>II</td><td>Advanced NSCLC</td><td>NCT03516981</td><td>Recruiting</td></tr><tr><td/><td>REGN3767 (Regeneron)</td><td>REGN2810</td><td>I</td><td>Advanced Cancers</td><td>NCT03005782</td><td>Recruiting</td></tr><tr><td/><td>TSR-033 (Tesaro)</td><td>Anti-PD-1</td><td>I</td><td>Advanced solid tumors</td><td>NCT03250832</td><td>Recruiting</td></tr><tr><td/><td>BI754111 (Bohringer Ingelheim)</td><td>BI754091</td><td>Early I</td><td>Neoplasms</td><td>NCT03433898</td><td>Recruiting</td></tr><tr><td/><td/><td>BI754091</td><td>I</td><td>Advanced cancers</td><td>NCT03156114</td><td>Recruiting</td></tr><tr><td/><td/><td>BI754091</td><td>I</td><td>Advanced NSCLC and HNSCC</td><td>NCT03780725</td><td>Recruiting</td></tr><tr><td/><td/><td>BI754091</td><td>II</td><td>Advanced solid tumors.</td><td>NCT03697304</td><td>Recruiting</td></tr><tr><td/><td/><td>BI754091, BI907828</td><td>I</td><td>Advanced solid tumors.</td><td>NCT03964233</td><td>Recruiting</td></tr><tr><td/><td>Sym022 (Symphogen)</td><td>&#x02013;</td><td>I</td><td>Advanced solid tumor or lymphomas</td><td>NCT03489369</td><td>Recruiting</td></tr><tr><td/><td/><td>Sym021, Sym023</td><td>I</td><td>Advanced solid tumor or lymphomas</td><td>NCT03311412</td><td>Recruiting</td></tr><tr><td/><td>FS118<sup><bold>a</bold></sup> (F-star)</td><td>&#x02013;</td><td>I</td><td>Advanced malignancies</td><td>NCT03440437</td><td>Recruiting</td></tr><tr><td/><td>MGD013<sup><bold>b</bold></sup> (MacroGenics)</td><td>&#x02013;</td><td>I</td><td>Advanced cancers</td><td>NCT03219268</td><td>Recruiting</td></tr><tr><td>TIM-3</td><td>TSR-022 (Tesaro)</td><td>TSR-042, TSR-033</td><td>I</td><td>Advanced solid tumors</td><td>NCT02817633</td><td>Recruiting</td></tr><tr><td/><td/><td><p>Niraparib, TSR-042, Bevacizumab,</p><p>Platinum-Based chemotherapy</p></td><td>I</td><td>Advanced solid tumors</td><td>NCT03307785</td><td>Recruiting</td></tr><tr><td/><td/><td>TSR-042</td><td>II</td><td>Liver Cancer</td><td>NCT03680508</td><td>Not yet recruiting</td></tr><tr><td/><td>MBG453 (Novartis)</td><td>PDR001</td><td>I/II</td><td>Advanced malignancies.</td><td>NCT02608268</td><td>Recruiting</td></tr><tr><td/><td/><td>Decitabine, PDR001</td><td>I</td><td>AML or high risk MDS</td><td>NCT03066648</td><td>Recruiting</td></tr><tr><td/><td/><td>HDM201, Venetoclax</td><td>I</td><td>AML or high risk MDS</td><td>NCT03940352</td><td>Recruiting</td></tr><tr><td/><td/><td>Spartalizumab</td><td>I</td><td>GBM</td><td>NCT03961971</td><td>Not yet recruiting</td></tr><tr><td/><td>Sym023 (Symphogen)</td><td>&#x02013;</td><td>I</td><td>Advanced solid tumor or lymphomas</td><td>NCT03489343</td><td>Recruiting</td></tr><tr><td/><td/><td>Sym021, Sym022</td><td>I</td><td>Advanced solid tumor or lymphomas</td><td>NCT03311412</td><td>Recruiting</td></tr><tr><td/><td>INCAGN2390 (Incyte)</td><td>&#x02013;</td><td>I</td><td>Advanced malignancies</td><td>NCT03652077</td><td>Recruiting</td></tr><tr><td/><td>LY3321367 (Eli Lilly and Company)</td><td>LY3300054</td><td>I</td><td>Advanced solid tumor</td><td>NCT03099109</td><td>Recruiting</td></tr><tr><td/><td/><td><p>LY3300054, Ramucirumab,</p><p>Abemaciclib, Merestinib</p></td><td>I</td><td>Advanced solid tumor</td><td>NCT02791334</td><td>Recruiting</td></tr><tr><td/><td>BMS-986258 (BMS)</td><td>Nivolumab, rHuPH20</td><td>I/II</td><td>Advanced solid tumor</td><td>NCT03446040</td><td>Recruiting</td></tr><tr><td/><td>SHR-1702 (Jiangsu HengRui)</td><td>Camrelizumab</td><td>I</td><td>Advanced solid tumor</td><td>NCT03871855</td><td>Not yet recruiting</td></tr><tr><td/><td>RO7121661<sup>c</sup> (Roche)</td><td>&#x02013;</td><td>I</td><td>Advanced solid tumor</td><td>NCT03708328</td><td>Recruiting</td></tr><tr><td>TIGIT</td><td>MK-7684 (Merck)</td><td>Pembrolizumab</td><td>I</td><td>Advanced solid tumor</td><td>NCT02964013</td><td>Recruiting</td></tr><tr><td/><td>Etigilimab /OMP-313&#x02009;M32 (OncoMed)</td><td>Nivolumab</td><td>I</td><td>Advanced solid tumor</td><td>NCT03119428</td><td>Active, not recruiting</td></tr><tr><td/><td>Tiragolumab/MTIG7192A/RG-6058 (Genentech)</td><td>Atezolizumab</td><td>I</td><td>Advanced solid tumor</td><td>NCT02794571</td><td>Active, not recruiting</td></tr><tr><td/><td/><td>Atezolizumab</td><td>II</td><td>Advanced NSCLC</td><td>NCT03563716</td><td>Active, not recruiting</td></tr><tr><td/><td>BMS-986207 (BMS)</td><td>Nivolumab</td><td>I/II</td><td>Advanced solid tumor</td><td>NCT02913313</td><td>Recruiting</td></tr><tr><td/><td>AB-154 (Arcus Biosciences)</td><td>AB122</td><td>I</td><td>Advanced malignancies</td><td>NCT03628677</td><td>Recruiting</td></tr><tr><td/><td>ASP-8374 (Potenza)</td><td>Pembrolizumab</td><td>I</td><td>Advanced solid tumors</td><td>NCT03260322</td><td>Recruiting</td></tr><tr><td/><td/><td>&#x02013;</td><td>I</td><td>Advanced solid tumor</td><td>NCT03945253</td><td>Not yet recruiting</td></tr><tr><td>VISTA</td><td>JNJ-61610588 (Johnson &#x00026; Johnson)</td><td>&#x02013;</td><td>I</td><td>Advanced solid tumor</td><td>NCT02671955</td><td>Terminated</td></tr><tr><td/><td>CA-170<sup>d</sup> (Curis)</td><td>&#x02013;</td><td>I</td><td>Advanced solid tumors and lymphomas</td><td>NCT02812875</td><td>Active, not recruiting</td></tr><tr><td>B7-H3</td><td>Enoblituzumab /MGA271 (MacroGenics)</td><td>&#x02013;</td><td>I</td><td>Advanced solid tumors</td><td>NCT01391143</td><td>Active, not recruiting</td></tr><tr><td/><td/><td>Ipilimumab</td><td>I</td><td>Advanced solid tumors</td><td>NCT02381314</td><td>Completed</td></tr><tr><td/><td/><td>Pembrolizumab</td><td>I</td><td>Advanced solid tumors</td><td>NCT02475213</td><td>Active, not recruiting</td></tr><tr><td/><td/><td>&#x02013;</td><td>I</td><td>Children with B7-H3-expressing solid tumors</td><td>NCT02982941</td><td>Completed</td></tr><tr><td/><td/><td>&#x02013;</td><td>II</td><td>Prostate cancer</td><td>NCT02923180</td><td>Recruiting</td></tr><tr><td/><td>MGD009<sup>e</sup> (MacroGenics)</td><td>MGA012</td><td>I</td><td>Advanced solid tumors</td><td>NCT03406949</td><td>Recruiting</td></tr><tr><td/><td/><td>&#x02013;</td><td>I</td><td>B7-H3-expressing tumors</td><td>NCT02628535</td><td>Recruiting</td></tr><tr><td/><td><sup>131</sup>I-8H9 /omburtamab (Y-mAbs)</td><td>&#x02013;</td><td>I</td><td>DSRCT</td><td>NCT01099644</td><td>Recruiting</td></tr><tr><td/><td/><td>&#x02013;</td><td>I</td><td>Advanced CNS or leptomeningeal cancer</td><td>NCT00089245</td><td>Recruiting</td></tr><tr><td/><td/><td>&#x02013;</td><td>II/III</td><td>Neuroblastoma central nervous system/leptomeningeal metastases</td><td>NCT03275402</td><td>Recruiting</td></tr><tr><td/><td><sup>124</sup>I-8H9 /omburtamab (Y-mAbs)</td><td>&#x02013;</td><td>I</td><td>Gliomas</td><td>NCT01502917</td><td>Recruiting</td></tr></tbody></table><table-wrap-foot><p>Abbreviation: <sup>a</sup>, a bispecific anti-LAG-3/PD-L1 antagonistic mAb; <sup>b</sup>, a bispecific anti-LAG-3/PD-1 antagonistic mAb; <sup>c</sup>, a bispecific anti-TIM-3/PD-1 antagonistic mAb; <sup>d</sup>, an oral inhibitor targeted PD-L1 and VISTA; <sup>e</sup>, a bispecific mAb designed to bind CD3 on T cells and B7-H3 on tumor; <italic>BMS</italic> Bristol-Myers Squibb, <italic>RCC</italic> Renal cell carcinoma, <italic>MBC</italic> Metastatic breast cancer, <italic>NSCLC</italic> Non-small cell lung cancer, <italic>HNSCC</italic> Squamous cell carcinoma of the head and neck, <italic>CRC</italic> Colorectal cancer, <italic>TNBC</italic> Triple Negative Breast Cancer, <italic>AML</italic> Acute Myeloid Leukemia, <italic>MDS</italic> Myelodysplastic, <italic>MSS</italic> Microsatellite stable, <italic>MSI-H</italic> Microsatellite instability high, <italic>GC</italic> Gastric Cancer, <italic>DSRCT</italic> Desmoplastic Small Round Cell Tumors, <italic>CNS</italic> Central nervous system, <italic>GBM</italic> Glioblastoma multiforme</p></table-wrap-foot></table-wrap></p><sec id="Sec4"><title>Lymphocyte activation Gene-3 (LAG-3)</title><sec id="Sec5"><title>The biology of LAG-3</title><p id="Par44">LAG-3 (CD223) was discovered by Triebel and colleagues as early as 1990 [<xref ref-type="bibr" rid="CR41">41</xref>]. The LAG-3 gene encompass 8 exons and the corresponding cDNA can encode a 498-amino acid type I membrane protein [<xref ref-type="bibr" rid="CR41">41</xref>]. LAG-3 gene is located adjacent to CD4 gene on chromosome 12, and further analysis of amino acid sequence reveals an approximately 20% identical to CD4 (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) [<xref ref-type="bibr" rid="CR41">41</xref>]. Mature LAG-3 protein includes four parts, hydrophobic leader, extracellular region, transmembrane region, and cytoplasmic region (Fig.<xref rid="Fig1" ref-type="fig">1</xref>). The extracellular region is consisted of four immunoglobulin (Ig) superfamily-like domains (D1-D4) [<xref ref-type="bibr" rid="CR42">42</xref>]. The membrane-distal D1 domain contains a unique short amino acid sequence, the so-called &#x0201c;extra loop&#x0201d; [<xref ref-type="bibr" rid="CR43">43</xref>]. The cytoplasmic domain of LAG-3 has three conserved regions: a serine-phosphorylation site, a KIEELE motif, and a glutamic acid-proline repeats, of which the KIEELE motif is essential for LAG-3 to exert inhibitory function [<xref ref-type="bibr" rid="CR44">44</xref>]. Metalloproteases can cleave LAG-3 within the connecting peptide between the D4 transmembrane domain and the transmembrane domain, generating a soluble LAG-3 (sLAG-3) [<xref ref-type="bibr" rid="CR45">45</xref>]. Some researches demonstrated that sLAG-3 could limit the magnitude of the T cell immune responses [<xref ref-type="bibr" rid="CR46">46</xref>]. LAG-3 is usually expressed on activated CD4<sup>+</sup> and CD8<sup>+</sup> T cells [<xref ref-type="bibr" rid="CR41">41</xref>], Tregs [<xref ref-type="bibr" rid="CR47">47</xref>], a subpopulation natural killer (NK) cells [<xref ref-type="bibr" rid="CR48">48</xref>], B cells [<xref ref-type="bibr" rid="CR49">49</xref>], plasmacytoid dendritic cells (pDCs) as well [<xref ref-type="bibr" rid="CR50">50</xref>]. Ample of evidence have indicated that LAG-3 signaling play a negative regulatory role in T helper 1 (Th1) cell activation, proliferation and cytokine secretion [<xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR53">53</xref>]. During tumorigenesis and cancer progression, tumor cells exploit this pathway to escape from immune surveillance.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Comparison of coinhibitory immune checkpoint receptors mentioned in manuscript</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Receptor</th><th>LAG-3</th><th>TIM-3</th><th>TIGIT</th><th>VISTA</th><th>B7-H3</th><th>BTLA</th></tr></thead><tbody><tr><td>Alternate name</td><td>CD223</td><td>HAVCR2</td><td><p>WUCAM/</p><p>Vstm3/ Vsig9</p></td><td><p>PD-1H/DD1&#x003b1;/</p><p>Gi24/Dies1/B7-H5</p></td><td>CD276</td><td>CD272</td></tr><tr><td>Chromosomal location</td><td>12p13.32</td><td>5q33.2</td><td>3q13.31</td><td>10q22.1</td><td>15q24.1</td><td>3q13.2</td></tr><tr><td>Function of ligand-receptor interaction</td><td>Co-inhibition</td><td>Co-inhibition</td><td>Co-inhibition</td><td>Co-inhibition</td><td>Co-inhibition or co-stimulation</td><td>Co-inhibition</td></tr><tr><td>Binding Partner</td><td>MHC-II, galectin-3, LSECtin, a-synuclein, FGL1</td><td>Galectin-9, Ceacam-1, HMGB-1, PtdSer</td><td>CD155, CD112</td><td>VSIG-3</td><td>Unknow</td><td>HVEM</td></tr><tr><td>Number of amino acids</td><td>498 amino acids</td><td>302 amino acids</td><td>244&#x000a0;amino acids</td><td>311 amino acids</td><td>316 amino acids</td><td>289 amino acids</td></tr><tr><td>Signaling motif</td><td>KIEELE motif</td><td>Tyrosine residues</td><td>ITT and ITIM</td><td>Unknow</td><td>Unknow</td><td>ITIM and ITSM</td></tr><tr><td>Receptor Expression</td><td>Activated T cells, B cells, Tregs, NK cells, DCs</td><td>Activated T cells, B cells, Tregs, DCs, NK cells, monocytes</td><td>T cells, NK cells</td><td>Myeloid cells, T cells</td><td>Activated T cells, NK cells, DCs, monocytes, tumor tissue</td><td>Mature B cells, T cells, Tregs, macrophages, DCs</td></tr></tbody></table></table-wrap>
<fig id="Fig1"><label>Fig. 1</label><caption><p>Structure of LAG-3, TIM-3, TIGIT, VISTA, B7-H3, and BTLA. All of them were type I transmembrane glycoprotein with a similar structure, including N-terminal IgV domain, a transmembrane domain and a cytoplasmic tail. However, they share distinct signaling motif</p></caption><graphic xlink:href="12943_2019_1091_Fig1_HTML" id="MO1"/></fig></p><p id="Par45">Based on the structural similarity between LAG-3 and CD4, MHC-II is reasonable considered as ligand for LAG-3. In fact, the binding affinity between LAG-3 and MHC-II is 100-fold higher than CD4 [<xref ref-type="bibr" rid="CR20">20</xref>]. Now, MHC-II [<xref ref-type="bibr" rid="CR54">54</xref>], galectin-3 [<xref ref-type="bibr" rid="CR55">55</xref>], LSECtin [<xref ref-type="bibr" rid="CR56">56</xref>], and a-synuclein [<xref ref-type="bibr" rid="CR57">57</xref>] have been described to interact with LAG-3, with the MHC-II as a canonical ligand (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). More recently, Wang and his co-workers elucidated that fibrinogen-like protein 1 (FGL1) was a novel high-affinity ligand for LAG-3 independent from MHC-II [<xref ref-type="bibr" rid="CR58">58</xref>].
<fig id="Fig2"><label>Fig. 2</label><caption><p>Current and emerging immune checkpoint receptors and their respective ligands. Various immune checkpoint molecules expressed on T cells were shown with their ligands. Immune checkpoints such as PD-1, CTLA-4, LAG-3, TIM-3, TIGIT bound with their respective ligands on APCs and/or tumor cells, triggering a negative or positive signal to T cells response</p></caption><graphic xlink:href="12943_2019_1091_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec6"><title>Clinical trials on LAG-3</title><p id="Par46">Based on the experimental results that administration of recombinant sLAG-3 molecule with irradiated tumor cells can dampen the growth of established tumors, early clinical work centered on developing a sLAG-3-Ig [<xref ref-type="bibr" rid="CR59">59</xref>]. IMP321 (Eftilagimod alpha) was initially developed as a vaccine immunological adjuvant [<xref ref-type="bibr" rid="CR60">60</xref>]. It is a soluble recombinant protein by fusing the four extracellular Ig domains of LAG-3 to the Fc portion of human IgG1 [<xref ref-type="bibr" rid="CR61">61</xref>]. The first-in-man phase I trial was conducted in patients with metastatic renal cell carcinoma (mRCC) (NCT00351949) [<xref ref-type="bibr" rid="CR62">62</xref>]. The results showed that adverse events (AEs) related to IMP321 were minimal and IMP321 increased the subset of circulating activated CD8<sup>+</sup> T cells which was correlated to tumor growth reduction. Although no objective response was observed in this trial, 7 of 8 patients experienced stable disease in higher IMP321 dose group (&#x0003e;&#x02009;6&#x02009;mg) while only 3 of 11 in the lower dose group [<xref ref-type="bibr" rid="CR62">62</xref>]. IMP321 monotherapy showed a modest efficacy in cancer therapy, thus it was rational to combine the agent with other chemotherapeutic drugs. Subsequently, another two clinical trials were lunched in metastatic breast cancer (MBC) (NCT00349934) [<xref ref-type="bibr" rid="CR63">63</xref>] and advanced pancreatic cancer (NCT00732082) [<xref ref-type="bibr" rid="CR64">64</xref>]. Ultimately, the former phase I/II trial showed a 50% objective response rate (ORR) at the end of treatment point, which compared favorably to a historical response rate of approximately 25% [<xref ref-type="bibr" rid="CR63">63</xref>]. Furthermore, the authors found an absolute and proportional increase in MHC class II-expressing APCs, NK cells and CD8<sup>+</sup> T cell populations and these subsets were known to connect with antitumor activity [<xref ref-type="bibr" rid="CR63">63</xref>]. This encouraging result has prompted a further phase IIb multicenter clinical trial that is currently recruiting patients with MBC (NCT02614833) [<xref ref-type="bibr" rid="CR65">65</xref>]. Unfortunately, the later phase I clinical trial intended to assess the role of IMP321 and gemcitabine as a front-line therapy in patients with pancreatic cancer showed no meaningful objective response [<xref ref-type="bibr" rid="CR64">64</xref>]. The role of IMP321 in combination with other immunotherapies (e.g., anti-PD-1 mAb, NCT03625323) or as an adjuvant for cancer vaccines are being explored (NCT00324623, NCT01308294) [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>].</p><p id="Par47">Relatlimab, also named BMS-986016, is the first commercially mAb directed against LAG-3 [<xref ref-type="bibr" rid="CR68">68</xref>]. Many preclinical mouse models have showed that PD-1/PD-L1 blockade upregulated LAG-3 or other immune checkpoints as a compensatory mechanism [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. These data evoked the further exploration of combination therapy strategies. For example, the first phase I clinical trial about Relatlimab was opened in 2013 (NCT01968109) [<xref ref-type="bibr" rid="CR38">38</xref>]. The aim of this clinical trial was to evaluate the efficacy of Relatlimab as a monotherapy or in combination with Nivolumab (anti-PD-1 antibody) in patients with various advanced malignancies including melanoma, NSCLC, and RCC [<xref ref-type="bibr" rid="CR20">20</xref>]. At ESMO 2017, researcher announced the updated efficacy and safety results in a cohort of 68 melanoma patients who had received prior immunotherapy [<xref ref-type="bibr" rid="CR70">70</xref>]. The ORR was 11.5% in 61 patients who were able to assess efficacy, including one patient achieved complete response and 6 were partial response (PR). Noticeably, the ORR was higher in patients with the expression of LAG-3&#x02009;&#x02265;&#x02009;1% and the AEs were tolerable [<xref ref-type="bibr" rid="CR70">70</xref>]. As of July 15, 2019, at least 18 clinical trials on Relatlimab had been registered on the <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link>. All of them were phase I or II but none of them are completed.</p><p id="Par48">LAG525 is another humanized anti-LAG-3 mAb. It is a high-affinity IgG4 antibody which blocks the binding of MHC-II to LAG-3. Currently, LAG525 is undergoing a series of phase I or II testing in combination with anti-PD-1 antibody for patients with advanced cancers. For example, LAG525&#x02019;s first clinical trial was launched in 2015 (NCT02460224). It was a phase I trial to determine the efficacy and safety of LAG525 plus PDR001 (anti-PD-1 mAb) in advanced malignancies [<xref ref-type="bibr" rid="CR36">36</xref>]. Other LAG-3 inhibitory antibodies MK-4280, REGN3767 [<xref ref-type="bibr" rid="CR71">71</xref>], TSR-033 [<xref ref-type="bibr" rid="CR72">72</xref>], BI754111 [<xref ref-type="bibr" rid="CR73">73</xref>], and Sym022 [<xref ref-type="bibr" rid="CR74">74</xref>] have also been investigated at various stages of clinical development. To capitalize on synergistic effects of co-blockade PD-1 and LAG-3 pathways in preclinical models [<xref ref-type="bibr" rid="CR75">75</xref>], some bispecific anti-LAG-3/PD-(L)1 antagonistic mAbs have also been developed, such as FS118 [<xref ref-type="bibr" rid="CR76">76</xref>] and MGD013 [<xref ref-type="bibr" rid="CR77">77</xref>]. To date, at least 10 kinds of LAG-3 blockade agents have been developed and studied in clinical trials, yet their results are not available now.</p></sec></sec><sec id="Sec7"><title>T cell immunoglobulin and mucin-domain containing-3 (TIM-3)</title><sec id="Sec8"><title>The biology of TIM-3</title><p id="Par49">TIM-3, also called hepatitis A virus cellular receptor 2 (HAVCR2), presents several unique features making it another intriguing immune checkpoint [<xref ref-type="bibr" rid="CR78">78</xref>]. It was first identified as a protein selectively expressed on CD4<sup>+</sup> Th1 and CD8<sup>+</sup> T cytotoxic 1 (Tc1) cells as early as 2002 [<xref ref-type="bibr" rid="CR21">21</xref>]. But now it is commonly classified as immune checkpoint molecule similar to CTLA-4 and PD-1. The genomic analysis shows that the TIM gene family is composed of three genes, namely TIM-1, TIM-3, TIM-4, located on human chromosome 5q33.2 [<xref ref-type="bibr" rid="CR79">79</xref>]. Human TIM-3 protein comprises of 302 amino acids, while mouse homolog includes 281 amino acids residues with 63% identity to human TIM-3 [<xref ref-type="bibr" rid="CR21">21</xref>]. It belongs to Ig superfamily (IgSF) with an N-terminal Ig variable region (IgV)-like domain, a membrane-proximal mucin-like domain containing sites for O-linked glycosylation (glycosylated mucin domain), a single transmembrane region and a C-terminal cytoplasmic tail. There are also sites for N-linked glycosylation between the mucin and transmembrane [<xref ref-type="bibr" rid="CR79">79</xref>]. The TIM-3 cytoplasmic tail does not have the classical inhibitory signaling motif, like immune receptor tyrosine based inhibitory motif (ITIM) or immune receptor tyrosine-based switch motif (ITSM), but contains five conserved tyrosine residues, two of which (Y265 and 272) can be phosphorylated by Src kinases or interleukin inducible T cell kinase and are crucial for downstream signaling [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. The expression of TIM-3 was not limited on T cell, it was known to express on different types of immune cells, including B cells, Tregs, NK cells, DCs, monocytes, and macrophages [<xref ref-type="bibr" rid="CR81">81</xref>]. Lately, the expression of TIM-3 has been identified in leukemic stem cells and tumor-associated endothelium [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>].</p><p id="Par50">Hitherto, four distinct ligands have been reported to bind to the IgV domain of TIM-3, including galectin-9, high-mobility group protein B1 (HMGB1), carcinoembryonic antigen cell adhesion molecule 1 (Ceacam-1), and phosphatidyl serine (PtdSer) [<xref ref-type="bibr" rid="CR84">84</xref>]. It is noteworthy that galectin-9 and HMGB1are soluble ligands, while Ceacam-1 and PtdSer belong to surface ligands. The engagement of TIM-3 with galectin-9 triggered intracellular calcium flux of Th1 cells, inducing cell death [<xref ref-type="bibr" rid="CR85">85</xref>]. Furthermore, a study by Kang et al. showed that galectin-9 also induced apoptosis of TIM-3<sup>+</sup>CD8<sup>+</sup>T cell in colon cancer [<xref ref-type="bibr" rid="CR86">86</xref>]. The interaction between HMGB1 and TIM-3 mainly had an impact on innate immune response. In tumor, TIM-3 was highly expressed on tumor infiltrating DCs and can compete with nucleic acid binding to HMGB1, therefore dampening anti-tumor immunity mediated by nucleic acids [<xref ref-type="bibr" rid="CR87">87</xref>]. Ceacam-1 was a molecule involved in T cell inhibition. Huang and his colleague elucidated that TIM-3 and Ceacam-1 can form a heterodimer in both <italic>cis</italic> and <italic>trans</italic> which acts as a negative regulator of T cell responses [<xref ref-type="bibr" rid="CR88">88</xref>]. The interaction of PtdSer with TIM-3 has been showed to connect with the clearance of apoptotic bodies and also improve the antigen cross-presentation [<xref ref-type="bibr" rid="CR89">89</xref>]. More importantly, higher expression of TIM-3 was associated with a poor prognosis in solid malignant [<xref ref-type="bibr" rid="CR90">90</xref>] and accumulating preclinical models have verified the therapeutic benefit of TIM-3 blockade by regulating TME and restricting tumor growth especially in combination with PD-1 blockade [<xref ref-type="bibr" rid="CR91">91</xref>].</p></sec><sec id="Sec9"><title>Clinical trials on TIM-3</title><p id="Par51">To date, at least eight TIM-3 antagonistic mAbs have been registered on <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link>. TSR-022 (Cobolimab), a novel IgG4 anti-TIM-3 mAb developed by Tesaro entered the first phase I clinical trial in 2016 (NCT02817633) [<xref ref-type="bibr" rid="CR92">92</xref>]. This multicenter, open-label study intended to evaluate the safety and efficacy of TSR-022 as a monotherapy or in combination with TSR-042 (anti-PD-1 mAb) in patients with advanced solid tumor. The results have been released in 2018 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Conference [<xref ref-type="bibr" rid="CR93">93</xref>]. Clinical benefits have been observed in the combination group, especially at a high dose of TSR-022 (300&#x02009;mg) with a 15% ORR (3/20) and 40% stable disease (8/20) [<xref ref-type="bibr" rid="CR93">93</xref>]. Another two clinical trials including TSR-022 are still recruiting patients with no clinical results available (NCT03307785, NCT03680508). MBG453 is another anti-TIM-3 mAb produced by Novartis. Similar to TSR-022, the first clinical trial aimed to assess the safety and efficacy of MBG453 as single agent or in combination with PDR001 (an anti-PD-1 mAb) in advanced malignancies patients (NCT02608268). Another clinical trial was conducted in patients with acute myelocytic leukemia or high-risk myelodysplastic syndromes (NCT03066648). Sym023, is a recombinant, fully human antibody that bound TIM-3 [<xref ref-type="bibr" rid="CR94">94</xref>]. A phase I trial evaluating the safety, tolerability, and dose-limiting toxicities of sym023 is recruiting at present (NCT03489343). Other TIM-3 inhibitors INCAGN2390, LY3321367, BMS-986258 and SHR1702 are also being tested in phase I trial alone (INCAGN02390 NCT03652077) or in combination with anti-PD-1/PD-L1 mAb (LY3321367 NCT03099109; BMS-986258 NCT03446040; SHR1702 NCT03871855) in the metastatic setting [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR95">95</xref>]. RO7121661 is a bispecific antibody targeting PD-1 and TIM-3 simultaneously. It was developed by Roche and a phase I dose escalation and expansion study has been ongoing on advanced solid tumors (NCT03708328).</p></sec></sec><sec id="Sec10"><title>T cell immunoglobulin and ITIM domain (TIGIT)</title><sec id="Sec11"><title>The biology of TIGIT</title><p id="Par52">TIGIT was first identified by Yu and his colleagues as an immune checkpoint rheostat that suppress the activation of T cells in 2009 [<xref ref-type="bibr" rid="CR22">22</xref>]. Subsequently, it was described by other groups with each group giving a different name including WUCAM [<xref ref-type="bibr" rid="CR96">96</xref>], Vstm3 [<xref ref-type="bibr" rid="CR97">97</xref>], and Vsig9 [<xref ref-type="bibr" rid="CR98">98</xref>]. TIGIT gene is located on human chromosome 3q13.31 and encodes a 244-amino acid transmembrane glycoprotein. The protein includes an extracellular IgV region, a transmembrane domain, and a cytoplasmic tail that harbors a canonical ITIM and an immunoglobulin tail tyrosine (ITT)-like phosphorylation motif [<xref ref-type="bibr" rid="CR22">22</xref>]. The expression of TIGIT was demonstrated to be tightly restricted to lymphocytes, mainly on T cell subsets (including Tregs and memory T cells) and NK cells [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR99">99</xref>]. TIGIT binds two ligands, namely CD155 (PVR or Necl-5) and CD112 (nectin-2, also known as PRR2 or PVRL2) with different affinity. Whether nectin-3 is another ligand for TIGIT is still in question [<xref ref-type="bibr" rid="CR99">99</xref>]. TIGIT exerts its immunosuppressive effects by competing with other counterparts, CD266 (DNAM-1) or CD96 [<xref ref-type="bibr" rid="CR100">100</xref>]. CD226 delivered a positive co-stimulatory signal, while TIGIT delivered inhibitory signals. This group of interacting proteins formed a co-stimulatory axis that are similar to the CTLA-4/B7/CD28 pathway [<xref ref-type="bibr" rid="CR101">101</xref>].</p><p id="Par53">As TIGIT was initially identified by a genomic search for structures shared a conserved ITIM motif, its immunosuppressive effects were delineated as expected. The initial research believed that TIGIT suppressed T cell activation in an indirect way. Specifically, the engagement of TIGIT with CD155 on DCs induced phosphorylation of CD155 and Erk, increased the secretion of IL-10, thus inhibiting T cell responses indirectly [<xref ref-type="bibr" rid="CR22">22</xref>]. Subsequent studies demonstrated that TIGIT could also directly suppress T cell function by competing with CD226 [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR102">102</xref>]. The role of TIGIT molecule in NK cells has been well studied. Stanietsky et al. indicated that ligation of TIGIT could lead to the inhibition of NK cells cytotoxicity through its cytoplasmic ITIM domain both in human and mouse [<xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]. Furthermore, the major role of ITT-like motif in negatively modulating NK cells has been proved by two independent studies [<xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR105">105</xref>]. Work from the Kurtulus group showed that the expression of TIGIT on Tregs was critically involved in Treg suppressive function [<xref ref-type="bibr" rid="CR106">106</xref>]. Interestingly, Gur and his co-works discovered that TIGIT could directly bind to the Fap2 protein derived from Fusobacterium nucleatum, triggering a negative signal to suppress the activities of NK cells and T cells, and hence mediating a tumor-immune evasion mechanism [<xref ref-type="bibr" rid="CR107">107</xref>]. Many groups generated agonistic anti-TIGIT mAb to verify the effect of TIGIT, indeed, they consistently reported a direct inhibitory effect on T cell proliferation [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]. Recently, some groups have reported that co-blockade of TIGIT with other checkpoint receptors, such as PD-1 and TIM-3, can exert synergistic effects in regulating antitumor responses [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR109">109</xref>, <xref ref-type="bibr" rid="CR110">110</xref>].</p></sec><sec id="Sec12"><title>Clinical trials on TIGIT</title><p id="Par54">Based on the promising preclinical results, targeting TIGIT as a strategy for cancer treatment attracts the attention of many pharmaceutical companies, especially combined with ant-PD-1/PD-L1 mAb. There are at least six major agents targeting TIGIT now, focusing on three products. MK-7684, a candidate anti-TIGIT drug developed by Merck entered into a phase I clinical trial to analysis the safety, efficacy, and pharmacokinetics of MK-7684 as monotherapy and in combination with pembrolizumab in metastatic solid tumors (NCT02964013) [<xref ref-type="bibr" rid="CR111">111</xref>]. The early phase I data was announced at the SITC&#x02019;s 3rd Annual Meeting in 2018. Sixty eight individuals were enrolled with 34 patients in the monotherapy and 34 patients in combination arms. Finally, one PR and eight PR were observed in these two groups, and the disease control rates were 35 and 47%, respectively [<xref ref-type="bibr" rid="CR112">112</xref>]. Etigilimab (OMP-313&#x02009;M32) is a humanized mAb that developed to block TIGIT from binding CD155. It was developed by OncoMed/Celgene and entered the first phase I clinical trial in April 2017 (NCT03119428). This open-label research was designed to evaluate the safety and tolerability of Etigilimab as a single agent or in combination with an anti-PD-1 mAb in patients with advanced malignancies. At the 2017 American Association for Cancer Research Annual Meeting, OncoMed presented some positive results from several preclinical trials, thus its clinic performance was worth pursuing [<xref ref-type="bibr" rid="CR111">111</xref>]. Another anti-TIGIT candidate drugs made by Genentech was named Tiragolumab (MTIG7192A, RG-6058). It&#x02019;s&#x000a0;also a fully human mAb designed to engage to TIGIT and hinder its interaction with CD155. There were two clinical trials about Tiragolumab registered on ClinicalTrials. gov (NCT02794571, NCT03563716). Other drugs, such as BMS-986207 made by Bristol-Myers Squibb, AB-154 made by Arcus biosciences and ASP-8374 made by Potenza also have initiated their phase I clinical trial with no clinical results reported [<xref ref-type="bibr" rid="CR111">111</xref>].</p></sec></sec><sec id="Sec13"><title>VISTA, B7-H3, BTLA, and Siglec-15</title><p id="Par55">Apart from these three new immune checkpoints mentioned above, many other immune checkpoint co-inhibitors are also attractive targets, with a few drugs step into clinical trials. VISTA, is also known as PD-1 homolog (PD-1H), DD1&#x003b1;, Gi24, differentiation of embryonic stem cells 1 (Dies1), and B7-H5 [<xref ref-type="bibr" rid="CR113">113</xref>]. It was first described as an IgSF ligand which can negatively regulate T cell responses in mouse [<xref ref-type="bibr" rid="CR23">23</xref>]. Subsequently, the same laboratory presented the characteristic of human VISTA [<xref ref-type="bibr" rid="CR114">114</xref>]. It is a type I transmembrane protein with an extracellular IgV domain, a stalk region, a transmembrane segment, and a cytoplasmic tail. Structural analysis shows that the IgV domain of VISTA shares a sequence homology both to CD28 and B7 families, while the full-length VISTA harbors a highest identity with PD-1 [<xref ref-type="bibr" rid="CR115">115</xref>]. But unlike PD-1, VISTA don&#x02019;t include a classical ITIM or ITSM motif in the cytoplasmic domain, the intracellular tail contains two potential protein kinase C binding sites and a proline rich motif that may function as docking sites, suggesting that VISTA has the potentially function as both a receptor and a ligand [<xref ref-type="bibr" rid="CR115">115</xref>]. Up to now the counter structures for VISTA has not been well identified [<xref ref-type="bibr" rid="CR116">116</xref>], and VSIG-3 was reported as a novel ligand for VISTA a short time ago [<xref ref-type="bibr" rid="CR117">117</xref>]. VISTA was highly expressed on myeloid cells and a lesser extent on T cells, but not on tumor cells within the TME [<xref ref-type="bibr" rid="CR118">118</xref>]. The preclinical studies on multiple murine models showed that VISTA blockade improved the infiltration, proliferation, and effector function of tumor-infiltrating T cells within the TME, thus altered the suppressive character of the TME [<xref ref-type="bibr" rid="CR118">118</xref>]. JNJ-61610588 is a fully human IgG1 anti-VISTA mAb made by Johnson &#x00026; Johnson. The phase I clinical trial was intended to evaluate safety and pharmacokinetics of JNJ-61610588 in patients with advanced cancers (NCT02671955) [<xref ref-type="bibr" rid="CR119">119</xref>]. Another candidate, CA-170, is an oral inhibitor which can selectively target both PD-L1 and VISTA. The results from preclinical models showed remarkable anti-tumor effects with well-tolerance and the phase I clinical trial in patients with advanced solid tumor and lymphomas is currently recruiting (NCT02812875) [<xref ref-type="bibr" rid="CR119">119</xref>]. Based on the newest result published by Blando et al., VISTA was regard as a promising target for patients with pancreatic cancer [<xref ref-type="bibr" rid="CR120">120</xref>] and the HMBD-002, a novel anti-VISTA antibody developed by Hummingbird Bioscience, have received a financial assistance from Cancer Prevention and Research Institute of Texas (CPRIT) with the plan to initiate clinical trials in 2020.</p><p id="Par56">B7-H3, also named CD276, is a type I transmembrane glycoprotein that is encoded on human chromosome 15 [<xref ref-type="bibr" rid="CR24">24</xref>]. It was discovered as early as 2001 [<xref ref-type="bibr" rid="CR24">24</xref>]. The initial study described it as a positive co-stimulator for it can stimulate the T cell response and IFN-&#x003b3; production [<xref ref-type="bibr" rid="CR24">24</xref>]. But recently studies reported that B7-H3 was involved in the inhibition of T cells [<xref ref-type="bibr" rid="CR121">121</xref>, <xref ref-type="bibr" rid="CR122">122</xref>]. The receptor for B7-H3 has not yet been identified and it may explain the intricate immunomodulatory activity of B7-H3 for it may have more than one binding partner with distinct function [<xref ref-type="bibr" rid="CR123">123</xref>]. The expression of B7-H3 protein can be detected on activated immune cells such as T cells, NK cells, and APCs. More importantly, it was overexpressed on a wide spectrum of tumor tissue and linked to disease states and prognosis [<xref ref-type="bibr" rid="CR124">124</xref>]. Recently, Enoblituzumab (MGA271), an engineered Fc humanized IgG1 mAb against B7-H3, has been developed and brought to clinic trials [<xref ref-type="bibr" rid="CR125">125</xref>]. Among the five clinical trials about Enoblituzumab, one of which had been completed but did not reported the final results. Another agents MGD009, is a bispecific mAb designed to bind both CD3 on T cells and B7-H3 on tumor cells [<xref ref-type="bibr" rid="CR36">36</xref>]. It is being studied on two phase I clinical studies in patients with B7-H3 expression (NCT02628535, NCT03406949) [<xref ref-type="bibr" rid="CR36">36</xref>]. Furthermore, 8H9 (omburtamab) is an antibody specific to B7-H3 [<xref ref-type="bibr" rid="CR126">126</xref>]. It has showed a positive clinical efficacy as an antibody drug conjugate after it was labeled with radioactive iodine-131 (<sup>131</sup>I) and administrated to patients with metastatic central nervous system (CNS) neuroblastoma [<xref ref-type="bibr" rid="CR127">127</xref>]. Currently, clinical trials with radiolabeled 8H9 have been evaluated on peritoneal cancers, gliomas, and CNS (NCT01099644, NCT01502917, NCT00089245 et al.) The newest result of NCT01502917 supported the further study in expanded cohort [<xref ref-type="bibr" rid="CR128">128</xref>].</p><p id="Par57">BTLA (CD272) is identified as another inhibitory receptor that belongs to CD28 superfamily [<xref ref-type="bibr" rid="CR113">113</xref>]. It is located on human chromosome 3 in q13.2 and encodes a 289-amino acid type I glycosylated transmembrane protein [<xref ref-type="bibr" rid="CR25">25</xref>]. Similar to PD-1 and CTLA-4, the protein structure of BTLA includes a single extracellular region, a transmembrane domain and cytoplasmic domain. The ITIM and ITSM within the cytoplasmic tail mediate a negative signaling to T cells by recruiting the SHP-1 and SHP-2 [<xref ref-type="bibr" rid="CR129">129</xref>]. BTLA was expressed on mature lymphocytes (such as B cells, T cells, and Tregs), macrophages, and mature bone marrow-derived DCs [<xref ref-type="bibr" rid="CR130">130</xref>]. Herpesvirus entry mediator (HVEM), a member of the tumor necrosis factor receptor superfamily (TNFRSF), was identified as the unique BTLA ligand in 2005 [<xref ref-type="bibr" rid="CR131">131</xref>]. But BTLA was not the unique binding partner for HVEM, it competed with other two TNF family members, LIGHT and lymphotoxin-&#x003b1;, as well as IgSF member CD160 for binding to HVEM [<xref ref-type="bibr" rid="CR132">132</xref>]. CD160 is another negative regulator of T cell while LIGHT is a costimulatory molecule [<xref ref-type="bibr" rid="CR133">133</xref>, <xref ref-type="bibr" rid="CR134">134</xref>]. The ligation of BTLA with HVEM triggered the inhibition of T cell proliferation and cytokine production [<xref ref-type="bibr" rid="CR131">131</xref>]. At present, there are no clinical trials opened for BTLA. But, in the past April, Junshi Biosciences announced that the world&#x02019;s first anti-BTLA mAb, TAB004/JS004, have been approved for clinical trial by FDA [<xref ref-type="bibr" rid="CR135">135</xref>].</p><p id="Par58">A recent publication reported a new immune suppressor, sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) [<xref ref-type="bibr" rid="CR136">136</xref>]. The team of Dr. Lieping Chen elegantly demonstrated the expression of Siglect-15 (mainly on cancer cells, macrophages, and myeloid cells) and the inhibitory role of Siglect-15 in regulation of T cell responses. More importantly, they revealed that both genetic ablation and antagonize antibody of Siglec-15 suppressed the growth of tumor in murine models [<xref ref-type="bibr" rid="CR136">136</xref>]. Right now, a clinical trial lead by Chen&#x02019;s group is recruiting to test the efficacy of NC318 (an anti-Siglec-15 mAb) in solid tumors (NCT03665285) [<xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR137">137</xref>].</p></sec></sec><sec id="Sec14"><title>Conclusion</title><p id="Par59">The success of CTLA-4 or PD-1/PD-L1 blockade catalyzed the enthusiasm for a new class of antibody that block negative immune checkpoint regulators for cancer therapy. The past two decades have witnessed the significant progress in identifying alternative targets and developing novel specific agents in treating cancer. As we described above, considerable immune checkpoints have been explored with some been chosen as novel therapeutic targets by pharmaceutical companies. Although the number of clinical trials about these emerging immune modulators, such as anti-LAG-3 antibody and anti-TIM-3 antibody, registered on <ext-link ext-link-type="uri" xlink:href="http://clinialtrial.gov">ClinialTrial.gov</ext-link> has grown exponentially, no drugs entered the clinic up to date. There are still some puzzles to be solved, like identification of ligand for VISTA and B7-H3 which may be the key to fully understand their therapeutic potential. In addition, while the results of monotherapy treatments are compelling, more attempts should be made to design rational combinations of immune-therapeutics that target non-redundant pathways to achieve synergistic effects in inhibiting tumor growth. We are still in the early stage of understanding these new immune systems with the aim that more candidates&#x02019; agents can transform to clinical fields and achieve even greater success than that initially observed with CTLA-4 or PD-1 blockade.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AEs</term><def><p id="Par2">Adverse events</p></def></def-item><def-item><term>B7-H3</term><def><p id="Par3">B7 homolog 3 protein</p></def></def-item><def-item><term>BTLA</term><def><p id="Par4">B and T cell lymphocyte attenuator</p></def></def-item><def-item><term>Ceacam-1</term><def><p id="Par5">Carcinoembryonic antigen cell adhesion molecule 1</p></def></def-item><def-item><term>CNS</term><def><p id="Par6">Central nervous system</p></def></def-item><def-item><term>CTLA-4</term><def><p id="Par7">Cytotoxic T lymphocyte-associated antigen-4</p></def></def-item><def-item><term>DC</term><def><p id="Par8">Dendritic cells</p></def></def-item><def-item><term>FDA</term><def><p id="Par9">United States Food and Drug Administration</p></def></def-item><def-item><term>HMGB1</term><def><p id="Par10">High-mobility group protein B1</p></def></def-item><def-item><term>HVEM</term><def><p id="Par11">Herpesvirus entry mediator</p></def></def-item><def-item><term>ICI</term><def><p id="Par12">Immune checkpoint inhibitor</p></def></def-item><def-item><term>IgSF</term><def><p id="Par13">Ig superfamily</p></def></def-item><def-item><term>IgV</term><def><p id="Par14">Ig variable region</p></def></def-item><def-item><term>ITIM</term><def><p id="Par15">Immune receptor tyrosine based inhibitory motif</p></def></def-item><def-item><term>ITSM</term><def><p id="Par16">Immune receptor tyrosine-based switch motif</p></def></def-item><def-item><term>ITT</term><def><p id="Par17">Immunoglobulin tail tyrosine</p></def></def-item><def-item><term>LAG-3</term><def><p id="Par18">Lymphocyte activation gene-3</p></def></def-item><def-item><term>mAb</term><def><p id="Par19">Monoclonal antibody</p></def></def-item><def-item><term>MBC</term><def><p id="Par20">Metastatic breast cancer</p></def></def-item><def-item><term>MHC</term><def><p id="Par21">Major histocompatibility complex</p></def></def-item><def-item><term>NK</term><def><p id="Par22">Natural killer</p></def></def-item><def-item><term>NSCLC</term><def><p id="Par23">Non-small cell lung cancer</p></def></def-item><def-item><term>ORR</term><def><p id="Par24">Objective response rate</p></def></def-item><def-item><term>PD-1</term><def><p id="Par25">Programmed cell death protein-1</p></def></def-item><def-item><term>PD-L1</term><def><p id="Par26">Programmed cell death ligand 1</p></def></def-item><def-item><term>PR</term><def><p id="Par27">Partial response</p></def></def-item><def-item><term>PtdSer</term><def><p id="Par28">Phosphatidyl serine</p></def></def-item><def-item><term>RCC</term><def><p id="Par29">Renal cell carcinoma</p></def></def-item><def-item><term>SHP1/2</term><def><p id="Par30">Src homology 2 domain containing phosphatases 1/2</p></def></def-item><def-item><term>Siglec-15</term><def><p id="Par31">Sialic acid-binding immunoglobulin-like lectin 15</p></def></def-item><def-item><term>SITC</term><def><p id="Par32">Society for Immunotherapy of Cancer</p></def></def-item><def-item><term>TCR</term><def><p id="Par33">T cell receptor</p></def></def-item><def-item><term>TIGIT</term><def><p id="Par34">T cell immunoglobulin and ITIM domain</p></def></def-item><def-item><term>TIM-3</term><def><p id="Par35">T cell immunoglobulin and mucin-domain containing-3</p></def></def-item><def-item><term>TME</term><def><p id="Par36">Tumor microenvironment</p></def></def-item><def-item><term>Tregs</term><def><p id="Par37">Regulatory T cells</p></def></def-item><def-item><term>VISTA</term><def><p id="Par38">V-domain Ig suppressor of T cell activation</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>SQ performed the selection of literature, drafted the manuscript, and prepared the Figs. LX, MY, and SY helped to collect literatures, participate in the discussion and revise the manuscript. SL and KW carried out the design of this review and revised the manuscript. All authors contributed to this manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the National Natural Science Foundation of China (No. 81572608, 81874120) and Wuhan Science and Technology Bureau (No. 2017060201010170).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par60">Not applicable.</p></notes><notes><title>Consent for publication</title><p id="Par61">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par62">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>M</given-names></name><name><surname>Jiao</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><etal/></person-group><article-title>Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors</article-title><source>Mol Cancer</source><year>2018</year><volume>17</volume><fpage>129</fpage><pub-id pub-id-type="doi">10.1186/s12943-018-0864-3</pub-id><pub-id pub-id-type="pmid">30139382</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><etal/></person-group><article-title>Chimeric antigen receptor T cells: a novel therapy for solid tumors</article-title><source>J Hematol Oncol</source><year>2017</year><volume>10</volume><fpage>78</fpage><pub-id pub-id-type="doi">10.1186/s13045-017-0444-9</pub-id><pub-id pub-id-type="pmid">28356156</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Jiao</surname><given-names>D</given-names></name><etal/></person-group><article-title>Recent advances of bispecific antibodies in solid tumors</article-title><source>J Hematol Oncol</source><year>2017</year><volume>10</volume><fpage>155</fpage><pub-id pub-id-type="doi">10.1186/s13045-017-0522-z</pub-id><pub-id pub-id-type="pmid">28931402</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballas</surname><given-names>ZK</given-names></name></person-group><article-title>The 2018 Nobel prize in physiology or medicine: an exemplar of bench to bedside in immunology</article-title><source>J Allergy Clin Immunol</source><year>2018</year><volume>142</volume><fpage>1752</fpage><lpage>1753</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2018.10.021</pub-id><pub-id pub-id-type="pmid">30539724</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>R</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name></person-group><article-title>PD-1, PD-L1 (B7-H1) and tumor-site immune modulation therapy: the historical perspective</article-title><source>J Hematol Oncol</source><year>2017</year><volume>10</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.1186/s13045-017-0403-5</pub-id><pub-id pub-id-type="pmid">28122590</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krummel</surname><given-names>MF</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name></person-group><article-title>CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation</article-title><source>J Exp Med</source><year>1995</year><volume>182</volume><fpage>459</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1084/jem.182.2.459</pub-id><pub-id pub-id-type="pmid">7543139</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity</article-title><source>Nat Rev Immunol</source><year>2004</year><volume>4</volume><fpage>336</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1038/nri1349</pub-id><pub-id pub-id-type="pmid">15122199</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leach</surname><given-names>D</given-names></name><name><surname>Krummel</surname><given-names>M</given-names></name><name><surname>Allison</surname><given-names>J</given-names></name></person-group><article-title>Enhancement of antitumor immunity by CTLA-4 blockade</article-title><source>Science (New York, NY)</source><year>1996</year><volume>271</volume><fpage>1734</fpage><lpage>1736</lpage><pub-id pub-id-type="doi">10.1126/science.271.5256.1734</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><etal/></person-group><article-title>Gut microbiome modulates efficacy of immune checkpoint inhibitors</article-title><source>J Hematol Oncol</source><year>2018</year><volume>11</volume><fpage>47</fpage><pub-id pub-id-type="doi">10.1186/s13045-018-0592-6</pub-id><pub-id pub-id-type="pmid">29580257</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>F</given-names></name><name><surname>Whiteside</surname><given-names>G</given-names></name><name><surname>Perry</surname><given-names>C</given-names></name></person-group><article-title>Ipilimumab: first global approval</article-title><source>Drugs.</source><year>2011</year><volume>71</volume><fpage>1093</fpage><lpage>1104</lpage><pub-id pub-id-type="doi">10.2165/11594010-000000000-00000</pub-id><pub-id pub-id-type="pmid">21668044</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okazaki</surname><given-names>T</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name></person-group><article-title>PD-1 and PD-1 ligands: from discovery to clinical application</article-title><source>Int Immunol</source><year>2007</year><volume>19</volume><fpage>813</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxm057</pub-id><pub-id pub-id-type="pmid">17606980</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Yin</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy</article-title><source>Oncogene.</source><year>2018</year><volume>37</volume><fpage>4941</fpage><lpage>4954</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0314-0</pub-id><pub-id pub-id-type="pmid">29786078</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>KN</given-names></name><name><surname>Pu</surname><given-names>JJ</given-names></name></person-group><article-title>PD-1 pathway and its clinical application: a 20year journey after discovery of the complete human PD-1 gene</article-title><source>Gene.</source><year>2018</year><volume>638</volume><fpage>20</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2017.09.050</pub-id><pub-id pub-id-type="pmid">28951311</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwok</surname><given-names>G</given-names></name><name><surname>Yau</surname><given-names>TC</given-names></name><name><surname>Chiu</surname><given-names>JW</given-names></name><name><surname>Tse</surname><given-names>E</given-names></name><name><surname>Kwong</surname><given-names>YL</given-names></name></person-group><article-title>Pembrolizumab (Keytruda)</article-title><source>Hum Vaccin Immunother</source><year>2016</year><volume>12</volume><fpage>2777</fpage><lpage>2789</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1199310</pub-id><pub-id pub-id-type="pmid">27398650</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuereder</surname><given-names>T</given-names></name></person-group><article-title>Immunotherapy for head and neck squamous cell carcinoma</article-title><source>Memo.</source><year>2016</year><volume>9</volume><fpage>66</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1007/s12254-016-0270-8</pub-id><pub-id pub-id-type="pmid">27429658</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>S</given-names></name><name><surname>Kerr</surname><given-names>KM</given-names></name><name><surname>Stahel</surname><given-names>R</given-names></name></person-group><article-title>PD-1 blockade in advanced NSCLC: a focus on pembrolizumab</article-title><source>Cancer Treat Rev</source><year>2018</year><volume>62</volume><fpage>39</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2017.10.002</pub-id><pub-id pub-id-type="pmid">29156447</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>de Wit</surname><given-names>R</given-names></name><name><surname>Vaughn</surname><given-names>DJ</given-names></name><name><surname>Fradet</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>JL</given-names></name><name><surname>Fong</surname><given-names>L</given-names></name><etal/></person-group><article-title>Pembrolizumab as second-line therapy for advanced urothelial carcinoma</article-title><source>New Engl J Med</source><year>2017</year><volume>376</volume><fpage>1015</fpage><lpage>1026</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1613683</pub-id><pub-id pub-id-type="pmid">28212060</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frenel</surname><given-names>JS</given-names></name><name><surname>Le Tourneau</surname><given-names>C</given-names></name><name><surname>O'Neil</surname><given-names>B</given-names></name><name><surname>Ott</surname><given-names>PA</given-names></name><name><surname>Piha-Paul</surname><given-names>SA</given-names></name><name><surname>Gomez-Roca</surname><given-names>C</given-names></name><etal/></person-group><article-title>Safety and efficacy of Pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial</article-title><source>J Clin Oncol</source><year>2017</year><volume>35</volume><fpage>4035</fpage><lpage>4041</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.74.5471</pub-id><pub-id pub-id-type="pmid">29095678</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Rubinstein</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name></person-group><article-title>Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China cancer immunotherapy workshop in Beijing</article-title><source>J Hematol Oncol</source><year>2018</year><volume>11</volume><fpage>142</fpage><pub-id pub-id-type="doi">10.1186/s13045-018-0684-3</pub-id><pub-id pub-id-type="pmid">30577797</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>LP</given-names></name><name><surname>Marciscano</surname><given-names>AE</given-names></name><name><surname>Drake</surname><given-names>CG</given-names></name><name><surname>Vignali</surname><given-names>DA</given-names></name></person-group><article-title>LAG3 (CD223) as a cancer immunotherapy target</article-title><source>Immunol Rev</source><year>2017</year><volume>276</volume><fpage>80</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1111/imr.12519</pub-id><pub-id pub-id-type="pmid">28258692</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monney</surname><given-names>L</given-names></name><name><surname>Sabatos</surname><given-names>CA</given-names></name><name><surname>Gaglia</surname><given-names>JL</given-names></name><name><surname>Ryu</surname><given-names>A</given-names></name><name><surname>Waldner</surname><given-names>H</given-names></name><name><surname>Chernova</surname><given-names>T</given-names></name><etal/></person-group><article-title>Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease</article-title><source>Nature.</source><year>2002</year><volume>415</volume><fpage>536</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1038/415536a</pub-id><pub-id pub-id-type="pmid">11823861</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Harden</surname><given-names>K</given-names></name><name><surname>Gonzalez</surname><given-names>LC</given-names></name><name><surname>Francesco</surname><given-names>M</given-names></name><name><surname>Chiang</surname><given-names>E</given-names></name><name><surname>Irving</surname><given-names>B</given-names></name><etal/></person-group><article-title>The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells</article-title><source>Nat Immunol</source><year>2009</year><volume>10</volume><fpage>48</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/ni.1674</pub-id><pub-id pub-id-type="pmid">19011627</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Rubinstein</surname><given-names>R</given-names></name><name><surname>Lines</surname><given-names>JL</given-names></name><name><surname>Wasiuk</surname><given-names>A</given-names></name><name><surname>Ahonen</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses</article-title><source>J Exp Med</source><year>2011</year><volume>208</volume><fpage>577</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1084/jem.20100619</pub-id><pub-id pub-id-type="pmid">21383057</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapoval</surname><given-names>AI</given-names></name><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Lau</surname><given-names>JS</given-names></name><name><surname>Wilcox</surname><given-names>RA</given-names></name><name><surname>Flies</surname><given-names>DB</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><etal/></person-group><article-title>B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production</article-title><source>Nat Immunol</source><year>2001</year><volume>2</volume><fpage>269</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1038/85339</pub-id><pub-id pub-id-type="pmid">11224528</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>R</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>BTLA/HVEM signaling: milestones in research and role in chronic hepatitis B virus infection</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>617</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00617</pub-id><pub-id pub-id-type="pmid">30984188</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharpe</surname><given-names>AH</given-names></name></person-group><article-title>Mechanisms of costimulation</article-title><source>Immunol Rev</source><year>2009</year><volume>229</volume><fpage>5</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2009.00784.x</pub-id><pub-id pub-id-type="pmid">19426211</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La-Beck</surname><given-names>NM</given-names></name><name><surname>Jean</surname><given-names>GW</given-names></name><name><surname>Huynh</surname><given-names>C</given-names></name><name><surname>Alzghari</surname><given-names>SK</given-names></name><name><surname>Lowe</surname><given-names>DB</given-names></name></person-group><article-title>Immune checkpoint inhibitors: new insights and current place in cancer therapy</article-title><source>Pharmacotherapy.</source><year>2015</year><volume>35</volume><fpage>963</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1002/phar.1643</pub-id><pub-id pub-id-type="pmid">26497482</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lizee</surname><given-names>G</given-names></name><name><surname>Overwijk</surname><given-names>WW</given-names></name><name><surname>Radvanyi</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Hwu</surname><given-names>P</given-names></name></person-group><article-title>Harnessing the power of the immune system to target cancer</article-title><source>Annu Rev Med</source><year>2013</year><volume>64</volume><fpage>71</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1146/annurev-med-112311-083918</pub-id><pub-id pub-id-type="pmid">23092383</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>CA</given-names></name><name><surname>Kuhns</surname><given-names>MS</given-names></name><name><surname>Egen</surname><given-names>JG</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name></person-group><article-title>CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy</article-title><source>Annu Rev Immunol</source><year>2001</year><volume>19</volume><fpage>565</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.19.1.565</pub-id><pub-id pub-id-type="pmid">11244047</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudd</surname><given-names>CE</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Schneider</surname><given-names>H</given-names></name></person-group><article-title>CD28 and CTLA-4 coreceptor expression and signal transduction</article-title><source>Immunol Rev</source><year>2009</year><volume>229</volume><fpage>12</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2009.00770.x</pub-id><pub-id pub-id-type="pmid">19426212</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Wagner</surname><given-names>K</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name></person-group><article-title>Novel cancer immunotherapy agents with survival benefit: recent successes and next steps</article-title><source>Nat Rev Cancer</source><year>2011</year><volume>11</volume><fpage>805</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1038/nrc3153</pub-id><pub-id pub-id-type="pmid">22020206</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardoll</surname><given-names>DM</given-names></name></person-group><article-title>The blockade of immune checkpoints in cancer immunotherapy</article-title><source>Nat Rev Cancer</source><year>2012</year><volume>12</volume><fpage>252</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1038/nrc3239</pub-id><pub-id pub-id-type="pmid">22437870</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boussiotis</surname><given-names>VA</given-names></name></person-group><article-title>Molecular and biochemical aspects of the PD-1 checkpoint pathway</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><fpage>1767</fpage><lpage>1778</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1514296</pub-id><pub-id pub-id-type="pmid">27806234</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Toor SM, Sasidharan Nair V, Decock J, Elkord E. Immune checkpoints in the tumor microenvironment. Semin Cancer Biol. 2019. 10.1016/j.semcancer.2019.06.021.</mixed-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Kuchroo</surname><given-names>VK</given-names></name></person-group><article-title>Tim-3 and its role in regulating anti-tumor immunity</article-title><source>Immunol Rev</source><year>2017</year><volume>276</volume><fpage>97</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1111/imr.12520</pub-id><pub-id pub-id-type="pmid">28258697</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marin-Acevedo</surname><given-names>JA</given-names></name><name><surname>Dholaria</surname><given-names>B</given-names></name><name><surname>Soyano</surname><given-names>AE</given-names></name><name><surname>Knutson</surname><given-names>KL</given-names></name><name><surname>Chumsri</surname><given-names>S</given-names></name><name><surname>Lou</surname><given-names>Y</given-names></name></person-group><article-title>Next generation of immune checkpoint therapy in cancer: new developments and challenges</article-title><source>J Hematol Oncol</source><year>2018</year><volume>11</volume><fpage>39</fpage><pub-id pub-id-type="doi">10.1186/s13045-018-0582-8</pub-id><pub-id pub-id-type="pmid">29544515</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>RY</given-names></name><name><surname>Eppolito</surname><given-names>C</given-names></name><name><surname>Lele</surname><given-names>S</given-names></name><name><surname>Shrikant</surname><given-names>P</given-names></name><name><surname>Matsuzaki</surname><given-names>J</given-names></name><name><surname>Odunsi</surname><given-names>K</given-names></name></person-group><article-title>LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model</article-title><source>Oncotarget.</source><year>2015</year><volume>6</volume><fpage>27359</fpage><lpage>27377</lpage><pub-id pub-id-type="pmid">26318293</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>RY</given-names></name><name><surname>Francois</surname><given-names>A</given-names></name><name><surname>McGray</surname><given-names>AR</given-names></name><name><surname>Miliotto</surname><given-names>A</given-names></name><name><surname>Odunsi</surname><given-names>K</given-names></name></person-group><article-title>Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer</article-title><source>Oncoimmunology.</source><year>2017</year><volume>6</volume><fpage>e1249561</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2016.1249561</pub-id><pub-id pub-id-type="pmid">28197366</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyama</surname><given-names>S</given-names></name><name><surname>Akbay</surname><given-names>EA</given-names></name><name><surname>Li</surname><given-names>YY</given-names></name><name><surname>Herter-Sprie</surname><given-names>GS</given-names></name><name><surname>Buczkowski</surname><given-names>KA</given-names></name><name><surname>Richards</surname><given-names>WG</given-names></name><etal/></person-group><article-title>Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><fpage>10501</fpage><pub-id pub-id-type="doi">10.1038/ncomms10501</pub-id><pub-id pub-id-type="pmid">26883990</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fourcade</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Benallaoua</surname><given-names>M</given-names></name><name><surname>Guillaume</surname><given-names>P</given-names></name><name><surname>Luescher</surname><given-names>IF</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><etal/></person-group><article-title>Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients</article-title><source>J Exp Med</source><year>2010</year><volume>207</volume><fpage>2175</fpage><lpage>2186</lpage><pub-id pub-id-type="doi">10.1084/jem.20100637</pub-id><pub-id pub-id-type="pmid">20819923</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Triebel</surname><given-names>F</given-names></name><name><surname>Jitsukawa</surname><given-names>S</given-names></name><name><surname>Baixeras</surname><given-names>E</given-names></name><name><surname>Roman-Roman</surname><given-names>S</given-names></name><name><surname>Genevee</surname><given-names>C</given-names></name><name><surname>Viegas-Pequignot</surname><given-names>E</given-names></name><etal/></person-group><article-title>LAG-3, a novel lymphocyte activation gene closely related to CD4</article-title><source>J Exp Med</source><year>1990</year><volume>171</volume><fpage>1393</fpage><lpage>1405</lpage><pub-id pub-id-type="doi">10.1084/jem.171.5.1393</pub-id><pub-id pub-id-type="pmid">1692078</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huard</surname><given-names>B</given-names></name><name><surname>Mastrangeli</surname><given-names>R</given-names></name><name><surname>Prigent</surname><given-names>P</given-names></name><name><surname>Bruniquel</surname><given-names>D</given-names></name><name><surname>Donini</surname><given-names>S</given-names></name><name><surname>El-Tayar</surname><given-names>N</given-names></name><etal/></person-group><article-title>Characterization of the major histocompatibility complex class II binding site on LAG-3 protein</article-title><source>Proc Natl Acad Sci U S A</source><year>1997</year><volume>94</volume><fpage>5744</fpage><lpage>5749</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.11.5744</pub-id><pub-id pub-id-type="pmid">9159144</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>MV</given-names></name><name><surname>Drake</surname><given-names>CG</given-names></name></person-group><article-title>LAG-3 in cancer immunotherapy</article-title><source>Curr Top Microbiol Immunol</source><year>2011</year><volume>344</volume><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">21086108</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Workman</surname><given-names>CJ</given-names></name><name><surname>Vignali</surname><given-names>DA</given-names></name></person-group><article-title>The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells</article-title><source>Eur J Immunol</source><year>2003</year><volume>33</volume><fpage>970</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1002/eji.200323382</pub-id><pub-id pub-id-type="pmid">12672063</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Workman</surname><given-names>CJ</given-names></name><name><surname>Martin</surname><given-names>SM</given-names></name><name><surname>Vignali</surname><given-names>DA</given-names></name></person-group><article-title>Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223)</article-title><source>J Immunol</source><year>2004</year><volume>173</volume><fpage>6806</fpage><lpage>6812</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.173.11.6806</pub-id><pub-id pub-id-type="pmid">15557174</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buisson</surname><given-names>S</given-names></name><name><surname>Triebel</surname><given-names>F</given-names></name></person-group><article-title>LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors</article-title><source>Immunology.</source><year>2005</year><volume>114</volume><fpage>369</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2004.02087.x</pub-id><pub-id pub-id-type="pmid">15720438</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>CT</given-names></name><name><surname>Workman</surname><given-names>CJ</given-names></name><name><surname>Flies</surname><given-names>D</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Marson</surname><given-names>AL</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><etal/></person-group><article-title>Role of LAG-3 in regulatory T cells</article-title><source>Immunity.</source><year>2004</year><volume>21</volume><fpage>503</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2004.08.010</pub-id><pub-id pub-id-type="pmid">15485628</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huard</surname><given-names>B</given-names></name><name><surname>Tournier</surname><given-names>M</given-names></name><name><surname>Triebel</surname><given-names>F</given-names></name></person-group><article-title>LAG-3 does not define a specific mode of natural killing in human</article-title><source>Immunol Lett</source><year>1998</year><volume>61</volume><fpage>109</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/S0165-2478(97)00170-3</pub-id><pub-id pub-id-type="pmid">9657262</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kisielow</surname><given-names>M</given-names></name><name><surname>Kisielow</surname><given-names>J</given-names></name><name><surname>Capoferri-Sollami</surname><given-names>G</given-names></name><name><surname>Karjalainen</surname><given-names>K</given-names></name></person-group><article-title>Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells</article-title><source>Eur J Immunol</source><year>2005</year><volume>35</volume><fpage>2081</fpage><lpage>2088</lpage><pub-id pub-id-type="doi">10.1002/eji.200526090</pub-id><pub-id pub-id-type="pmid">15971272</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreae</surname><given-names>S</given-names></name><name><surname>Piras</surname><given-names>F</given-names></name><name><surname>Burdin</surname><given-names>N</given-names></name><name><surname>Triebel</surname><given-names>F</given-names></name></person-group><article-title>Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223)</article-title><source>J Immunol</source><year>2002</year><volume>168</volume><fpage>3874</fpage><lpage>3880</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.168.8.3874</pub-id><pub-id pub-id-type="pmid">11937541</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huard</surname><given-names>B</given-names></name><name><surname>Prigent</surname><given-names>P</given-names></name><name><surname>Tournier</surname><given-names>M</given-names></name><name><surname>Bruniquel</surname><given-names>D</given-names></name><name><surname>Triebel</surname><given-names>F</given-names></name></person-group><article-title>CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins</article-title><source>Eur J Immunol</source><year>1995</year><volume>25</volume><fpage>2718</fpage><lpage>2721</lpage><pub-id pub-id-type="doi">10.1002/eji.1830250949</pub-id><pub-id pub-id-type="pmid">7589152</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macon-Lemaitre</surname><given-names>L</given-names></name><name><surname>Triebel</surname><given-names>F</given-names></name></person-group><article-title>The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells</article-title><source>Immunology.</source><year>2005</year><volume>115</volume><fpage>170</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2005.02145.x</pub-id><pub-id pub-id-type="pmid">15885122</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Workman</surname><given-names>CJ</given-names></name><name><surname>Dugger</surname><given-names>KJ</given-names></name><name><surname>Vignali</surname><given-names>DA</given-names></name></person-group><article-title>Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><fpage>5392</fpage><lpage>5395</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.169.10.5392</pub-id><pub-id pub-id-type="pmid">12421911</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baixeras</surname><given-names>E</given-names></name><name><surname>Huard</surname><given-names>B</given-names></name><name><surname>Miossec</surname><given-names>C</given-names></name><name><surname>Jitsukawa</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Hercend</surname><given-names>T</given-names></name><etal/></person-group><article-title>Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens</article-title><source>J Exp Med</source><year>1992</year><volume>176</volume><fpage>327</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1084/jem.176.2.327</pub-id><pub-id pub-id-type="pmid">1380059</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kouo</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Pucsek</surname><given-names>AB</given-names></name><name><surname>Cao</surname><given-names>M</given-names></name><name><surname>Solt</surname><given-names>S</given-names></name><name><surname>Armstrong</surname><given-names>T</given-names></name><etal/></person-group><article-title>Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of Plasmacytoid dendritic cells</article-title><source>Cancer Immunol Res</source><year>2015</year><volume>3</volume><fpage>412</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-14-0150</pub-id><pub-id pub-id-type="pmid">25691328</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses</article-title><source>Cancer Res</source><year>2014</year><volume>74</volume><fpage>3418</fpage><lpage>3428</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2690</pub-id><pub-id pub-id-type="pmid">24769443</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="other">Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, et al. Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science (New York, NY). 2016;353:aah3374</mixed-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Sanmamed</surname><given-names>MF</given-names></name><name><surname>Datar</surname><given-names>I</given-names></name><name><surname>Su</surname><given-names>TT</given-names></name><name><surname>Ji</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><etal/></person-group><article-title>Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3</article-title><source>Cell</source><year>2019</year><volume>176</volume><fpage>334</fpage><lpage>347.e12</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.11.010</pub-id><pub-id pub-id-type="pmid">30580966</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prigent</surname><given-names>P</given-names></name><name><surname>El Mir</surname><given-names>S</given-names></name><name><surname>Dreano</surname><given-names>M</given-names></name><name><surname>Triebel</surname><given-names>F</given-names></name></person-group><article-title>Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses</article-title><source>Eur J Immunol</source><year>1999</year><volume>29</volume><fpage>3867</fpage><lpage>3876</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1521-4141(199912)29:12&#x0003c;3867::AID-IMMU3867&#x0003e;3.0.CO;2-E</pub-id><pub-id pub-id-type="pmid">10601994</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fougeray</surname><given-names>S</given-names></name><name><surname>Brignone</surname><given-names>C</given-names></name><name><surname>Triebel</surname><given-names>F</given-names></name></person-group><article-title>A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: preclinical evaluation of IMP321</article-title><source>Vaccine.</source><year>2006</year><volume>24</volume><fpage>5426</fpage><lpage>5433</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.03.050</pub-id><pub-id pub-id-type="pmid">16621192</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huard</surname><given-names>B</given-names></name><name><surname>Prigent</surname><given-names>P</given-names></name><name><surname>Pages</surname><given-names>F</given-names></name><name><surname>Bruniquel</surname><given-names>D</given-names></name><name><surname>Triebel</surname><given-names>F</given-names></name></person-group><article-title>T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding</article-title><source>Eur J Immunol</source><year>1996</year><volume>26</volume><fpage>1180</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1002/eji.1830260533</pub-id><pub-id pub-id-type="pmid">8647185</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brignone</surname><given-names>C</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Grygar</surname><given-names>C</given-names></name><name><surname>Marcu</surname><given-names>M</given-names></name><name><surname>Triebel</surname><given-names>F</given-names></name></person-group><article-title>A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>6225</fpage><lpage>6231</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-0068</pub-id><pub-id pub-id-type="pmid">19755389</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brignone</surname><given-names>C</given-names></name><name><surname>Gutierrez</surname><given-names>M</given-names></name><name><surname>Mefti</surname><given-names>F</given-names></name><name><surname>Brain</surname><given-names>E</given-names></name><name><surname>Jarcau</surname><given-names>R</given-names></name><name><surname>Cvitkovic</surname><given-names>F</given-names></name><etal/></person-group><article-title>First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity</article-title><source>J Transl Med</source><year>2010</year><volume>8</volume><fpage>71</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-8-71</pub-id><pub-id pub-id-type="pmid">20653948</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang-Gillam</surname><given-names>A</given-names></name><name><surname>Plambeck-Suess</surname><given-names>S</given-names></name><name><surname>Goedegebuure</surname><given-names>P</given-names></name><name><surname>Simon</surname><given-names>PO</given-names></name><name><surname>Mitchem</surname><given-names>JB</given-names></name><name><surname>Hornick</surname><given-names>JR</given-names></name><etal/></person-group><article-title>A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma</article-title><source>Invest New Drugs</source><year>2013</year><volume>31</volume><fpage>707</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1007/s10637-012-9866-y</pub-id><pub-id pub-id-type="pmid">22864469</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dirix</surname><given-names>L</given-names></name><name><surname>Triebel</surname><given-names>F</given-names></name></person-group><article-title>AIPAC: a phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer</article-title><source>Future Oncol</source><year>2019</year><volume>15</volume><fpage>1963</fpage><lpage>1973</lpage><pub-id pub-id-type="doi">10.2217/fon-2018-0807</pub-id><pub-id pub-id-type="pmid">30977393</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>E</given-names></name><name><surname>Michielin</surname><given-names>O</given-names></name><name><surname>Voelter</surname><given-names>V</given-names></name><name><surname>Laurent</surname><given-names>J</given-names></name><name><surname>Bichat</surname><given-names>H</given-names></name><name><surname>Stravodimou</surname><given-names>A</given-names></name><etal/></person-group><article-title>MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a phase I trial</article-title><source>J Transl Med</source><year>2014</year><volume>12</volume><fpage>97</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-12-97</pub-id><pub-id pub-id-type="pmid">24726012</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legat</surname><given-names>A</given-names></name><name><surname>Maby-El Hajjami</surname><given-names>H</given-names></name><name><surname>Baumgaertner</surname><given-names>P</given-names></name><name><surname>Cagnon</surname><given-names>L</given-names></name><name><surname>Abed Maillard</surname><given-names>S</given-names></name><name><surname>Geldhof</surname><given-names>C</given-names></name><etal/></person-group><article-title>Vaccination with LAG-3Ig (IMP321) and peptides induces specific CD4 and CD8 T-cell responses in metastatic melanoma patients--report of a phase I/IIa clinical trial</article-title><source>Clin Cancer Res</source><year>2016</year><volume>22</volume><fpage>1330</fpage><lpage>1340</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-1212</pub-id><pub-id pub-id-type="pmid">26500235</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Pu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy</article-title><source>MAbs.</source><year>2019</year><volume>11</volume><fpage>1139</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1080/19420862.2019.1629239</pub-id><pub-id pub-id-type="pmid">31242068</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wierz</surname><given-names>M</given-names></name><name><surname>Pierson</surname><given-names>S</given-names></name><name><surname>Guyonnet</surname><given-names>L</given-names></name><name><surname>Viry</surname><given-names>E</given-names></name><name><surname>Lequeux</surname><given-names>A</given-names></name><name><surname>Oudin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia</article-title><source>Blood.</source><year>2018</year><volume>131</volume><fpage>1617</fpage><lpage>1621</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-06-792267</pub-id><pub-id pub-id-type="pmid">29439955</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwiatkowska</surname><given-names>D</given-names></name><name><surname>Kluska</surname><given-names>P</given-names></name><name><surname>Reich</surname><given-names>A</given-names></name></person-group><article-title>Beyond PD-1 immunotherapy in malignant melanoma</article-title><source>Dermatol Ther</source><year>2019</year><volume>9</volume><fpage>243</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1007/s13555-019-0292-3</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papadopoulos</surname><given-names>Kyriakos P.</given-names></name><name><surname>Lakhani</surname><given-names>Nehal J.</given-names></name><name><surname>Johnson</surname><given-names>Melissa Lynne</given-names></name><name><surname>Park</surname><given-names>Haeseong</given-names></name><name><surname>Wang</surname><given-names>Ding</given-names></name><name><surname>Yap</surname><given-names>Timothy Anthony</given-names></name><name><surname>Moore</surname><given-names>Kathleen N.</given-names></name><name><surname>Sims</surname><given-names>Tasha Nicholle</given-names></name><name><surname>Emeremni</surname><given-names>Chetachi</given-names></name><name><surname>Karasarides</surname><given-names>Maria</given-names></name><name><surname>Kroog</surname><given-names>Glenn Scott</given-names></name></person-group><article-title>A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody, in advanced cancers</article-title><source>Journal of Clinical Oncology</source><year>2018</year><volume>36</volume><issue>15_suppl</issue><fpage>TPS3127</fpage><lpage>TPS3127</lpage><pub-id pub-id-type="doi">10.1200/JCO.2018.36.15_suppl.TPS3127</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>Srimoyee</given-names></name><name><surname>Sharma</surname><given-names>Geeta</given-names></name><name><surname>Travers</surname><given-names>Jon</given-names></name><name><surname>Kumar</surname><given-names>Sujatha</given-names></name><name><surname>Choi</surname><given-names>Justin</given-names></name><name><surname>Jun</surname><given-names>H. Toni</given-names></name><name><surname>Kehry</surname><given-names>Marilyn</given-names></name><name><surname>Ramaswamy</surname><given-names>Sridhar</given-names></name><name><surname>Jenkins</surname><given-names>David</given-names></name></person-group><article-title>TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo</article-title><source>Molecular Cancer Therapeutics</source><year>2018</year><volume>18</volume><issue>3</issue><fpage>632</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-18-0836</pub-id><pub-id pub-id-type="pmid">30587557</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zettl</surname><given-names>M</given-names></name><name><surname>Wurm</surname><given-names>M</given-names></name><name><surname>Schaaf</surname><given-names>O</given-names></name><name><surname>Tirapu</surname><given-names>I</given-names></name><name><surname>Mostbock</surname><given-names>S</given-names></name><name><surname>Reschke</surname><given-names>M</given-names></name><etal/></person-group><article-title>Characterization of the LAG-3 targeting antibody BI 754111 in monotherapy and in combination with the anti-PD-1 antibody BI 754091</article-title><source>Cancer Res</source><year>2018</year><volume>78</volume><issue>suppl</issue><fpage>4547</fpage></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandal</surname><given-names>MM</given-names></name><name><surname>Melander</surname><given-names>MC</given-names></name><name><surname>Bhatia</surname><given-names>VK</given-names></name><name><surname>Gjetting</surname><given-names>T</given-names></name><name><surname>Lindsted</surname><given-names>T</given-names></name><name><surname>Frohlich</surname><given-names>C</given-names></name><etal/></person-group><article-title>Preclinical characterization of Sym022, a novel anti-LAG3 antibody</article-title><source>Cancer Res</source><year>2018</year><volume>78</volume><issue>suppl</issue><fpage>5626</fpage></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>SR</given-names></name><name><surname>Turnis</surname><given-names>ME</given-names></name><name><surname>Goldberg</surname><given-names>MV</given-names></name><name><surname>Bankoti</surname><given-names>J</given-names></name><name><surname>Selby</surname><given-names>M</given-names></name><name><surname>Nirschl</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape</article-title><source>Cancer Res</source><year>2012</year><volume>72</volume><fpage>917</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1620</pub-id><pub-id pub-id-type="pmid">22186141</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraman</surname><given-names>M</given-names></name><name><surname>Fosh</surname><given-names>N</given-names></name><name><surname>Kmiecik</surname><given-names>K</given-names></name><name><surname>Everett</surname><given-names>K</given-names></name><name><surname>Zimarino</surname><given-names>C</given-names></name><name><surname>Faroudi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Dual blockade of PD-L1 and LAG-3 with FS118, a unique bispecific antibody, induces CD8+T-cell activation and modulates the tumor microenvironment to promote antitumor immune responses</article-title><source>Cancer Res</source><year>2018</year><volume>78</volume><issue>suppl</issue><fpage>2719</fpage></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Motte-Mohs</surname><given-names>R</given-names></name><name><surname>Shah</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>JG</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Gorlatov</surname><given-names>S</given-names></name><name><surname>Ciccarone</surname><given-names>V</given-names></name><etal/></person-group><article-title>Preclinical characterization of MGD013, a PD-1 x LAG-3 bispecific DART (R) molecule</article-title><source>J Immunother Cancer</source><year>2017</year><volume>5</volume><issue>suppl 2</issue><fpage>P337</fpage></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Hirsch</surname><given-names>FR</given-names></name></person-group><article-title>TIM-3, a promising target for cancer immunotherapy</article-title><source>OncoTargets Ther</source><year>2018</year><volume>11</volume><fpage>7005</fpage><lpage>7009</lpage><pub-id pub-id-type="doi">10.2147/OTT.S170385</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyers</surname><given-names>JH</given-names></name><name><surname>Sabatos</surname><given-names>CA</given-names></name><name><surname>Chakravarti</surname><given-names>S</given-names></name><name><surname>Kuchroo</surname><given-names>VK</given-names></name></person-group><article-title>The TIM gene family regulates autoimmune and allergic diseases</article-title><source>Trends Mol Med</source><year>2005</year><volume>11</volume><fpage>362</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2005.06.008</pub-id><pub-id pub-id-type="pmid">16002337</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Weyer</surname><given-names>PS</given-names></name><name><surname>Muehlfeit</surname><given-names>M</given-names></name><name><surname>Klose</surname><given-names>C</given-names></name><name><surname>Bonventre</surname><given-names>JV</given-names></name><name><surname>Walz</surname><given-names>G</given-names></name><name><surname>Kuehn</surname><given-names>EW</given-names></name></person-group><article-title>A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9</article-title><source>Biochem Biophys Res Commun</source><year>2006</year><volume>351</volume><fpage>571</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2006.10.079</pub-id><pub-id pub-id-type="pmid">17069754</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>AC</given-names></name></person-group><article-title>Tim-3, a negative regulator of anti-tumor immunity</article-title><source>Curr Opin Immunol</source><year>2012</year><volume>24</volume><fpage>213</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2011.12.005</pub-id><pub-id pub-id-type="pmid">22226204</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jan</surname><given-names>M</given-names></name><name><surname>Chao</surname><given-names>MP</given-names></name><name><surname>Cha</surname><given-names>AC</given-names></name><name><surname>Alizadeh</surname><given-names>AA</given-names></name><name><surname>Gentles</surname><given-names>AJ</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name><etal/></person-group><article-title>Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>5009</fpage><lpage>5014</lpage><pub-id pub-id-type="doi">10.1073/pnas.1100551108</pub-id><pub-id pub-id-type="pmid">21383193</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion</article-title><source>J Exp Med</source><year>2010</year><volume>207</volume><fpage>505</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1084/jem.20090397</pub-id><pub-id pub-id-type="pmid">20176801</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><article-title>Tim-3 expression and its role in hepatocellular carcinoma</article-title><source>J Hematol Oncol</source><year>2018</year><volume>11</volume><fpage>126</fpage><pub-id pub-id-type="doi">10.1186/s13045-018-0667-4</pub-id><pub-id pub-id-type="pmid">30309387</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>AC</given-names></name><name><surname>Schubart</surname><given-names>A</given-names></name><name><surname>Xiong</surname><given-names>H</given-names></name><name><surname>Imitola</surname><given-names>J</given-names></name><name><surname>Khoury</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity</article-title><source>Nat Immunol</source><year>2005</year><volume>6</volume><fpage>1245</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1038/ni1271</pub-id><pub-id pub-id-type="pmid">16286920</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>CW</given-names></name><name><surname>Dutta</surname><given-names>A</given-names></name><name><surname>Chang</surname><given-names>LY</given-names></name><name><surname>Mahalingam</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Chiang</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>15659</fpage><pub-id pub-id-type="doi">10.1038/srep15659</pub-id><pub-id pub-id-type="pmid">26493689</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiba</surname><given-names>S</given-names></name><name><surname>Baghdadi</surname><given-names>M</given-names></name><name><surname>Akiba</surname><given-names>H</given-names></name><name><surname>Yoshiyama</surname><given-names>H</given-names></name><name><surname>Kinoshita</surname><given-names>I</given-names></name><name><surname>Dosaka-Akita</surname><given-names>H</given-names></name><etal/></person-group><article-title>Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1</article-title><source>Nat Immunol</source><year>2012</year><volume>13</volume><fpage>832</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1038/ni.2376</pub-id><pub-id pub-id-type="pmid">22842346</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>YH</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Kondo</surname><given-names>Y</given-names></name><name><surname>Anderson</surname><given-names>AC</given-names></name><name><surname>Gandhi</surname><given-names>A</given-names></name><name><surname>Russell</surname><given-names>A</given-names></name><etal/></person-group><article-title>CEACAM1 regulates TIM-3-mediated tolerance and exhaustion</article-title><source>Nature.</source><year>2015</year><volume>517</volume><fpage>386</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1038/nature13848</pub-id><pub-id pub-id-type="pmid">25363763</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>Akiba</surname><given-names>H</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Kojima</surname><given-names>Y</given-names></name><name><surname>Hashiguchi</surname><given-names>M</given-names></name><name><surname>Azuma</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation</article-title><source>Blood.</source><year>2009</year><volume>113</volume><fpage>3821</fpage><lpage>3830</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-10-185884</pub-id><pub-id pub-id-type="pmid">19224762</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>P</given-names></name><name><surname>Liang</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name></person-group><article-title>TIM-3 is a potential prognostic marker for patients with solid tumors: a systematic review and meta-analysis</article-title><source>Oncotarget.</source><year>2017</year><volume>8</volume><fpage>31705</fpage><lpage>31713</lpage><pub-id pub-id-type="pmid">28423646</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>AW</given-names></name><name><surname>Gill</surname><given-names>DM</given-names></name><name><surname>Pal</surname><given-names>SK</given-names></name><name><surname>Agarwal</surname><given-names>N</given-names></name></person-group><article-title>The future of immune checkpoint cancer therapy after PD-1 and CTLA-4</article-title><source>Immunotherapy.</source><year>2017</year><volume>9</volume><fpage>681</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.2217/imt-2017-0024</pub-id><pub-id pub-id-type="pmid">28653573</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murtaza</surname><given-names>A</given-names></name><name><surname>Laken</surname><given-names>H</given-names></name><name><surname>Correia</surname><given-names>JDS</given-names></name><name><surname>McNeeley</surname><given-names>P</given-names></name><name><surname>Altobell</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody</article-title><source>Eur J Cancer</source><year>2016</year><volume>69</volume><issue>Suppl 1</issue><fpage>S102</fpage><pub-id pub-id-type="doi">10.1016/S0959-8049(16)32903-3</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name></person-group><article-title>FcgammaR-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>292</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00292</pub-id><pub-id pub-id-type="pmid">30863404</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindsted</surname><given-names>T</given-names></name><name><surname>Gad</surname><given-names>M</given-names></name><name><surname>Grandal</surname><given-names>MV</given-names></name><name><surname>Frolich</surname><given-names>C</given-names></name><name><surname>Bhatia</surname><given-names>VK</given-names></name><name><surname>Gjetting</surname><given-names>T</given-names></name><etal/></person-group><article-title>Preclinical characterization of Sym023 a human anti-TIM3 antibody with a novel mechanism of action</article-title><source>Cancer Res</source><year>2018</year><volume>78</volume><issue>Suppl</issue><fpage>5629</fpage></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mollica</surname><given-names>V</given-names></name><name><surname>Di Nunno</surname><given-names>V</given-names></name><name><surname>Gatto</surname><given-names>L</given-names></name><name><surname>Santoni</surname><given-names>M</given-names></name><name><surname>Cimadamore</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><etal/></person-group><article-title>Novel therapeutic approaches and targets currently under evaluation for renal cell carcinoma: waiting for the revolution</article-title><source>Clin Drug Investig</source><year>2019</year><volume>39</volume><fpage>503</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1007/s40261-019-00773-w</pub-id><pub-id pub-id-type="pmid">30937824</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boles</surname><given-names>KS</given-names></name><name><surname>Vermi</surname><given-names>W</given-names></name><name><surname>Facchetti</surname><given-names>F</given-names></name><name><surname>Fuchs</surname><given-names>A</given-names></name><name><surname>Wilson</surname><given-names>TJ</given-names></name><name><surname>Diacovo</surname><given-names>TG</given-names></name><etal/></person-group><article-title>A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC</article-title><source>Eur J Immunol</source><year>2009</year><volume>39</volume><fpage>695</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1002/eji.200839116</pub-id><pub-id pub-id-type="pmid">19197944</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>SD</given-names></name><name><surname>Taft</surname><given-names>DW</given-names></name><name><surname>Brandt</surname><given-names>CS</given-names></name><name><surname>Bucher</surname><given-names>C</given-names></name><name><surname>Howard</surname><given-names>ED</given-names></name><name><surname>Chadwick</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Vstm3 is a member of the CD28 family and an important modulator of T-cell function</article-title><source>Eur J Immunol</source><year>2011</year><volume>41</volume><fpage>902</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1002/eji.201041136</pub-id><pub-id pub-id-type="pmid">21416464</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>AC</given-names></name><name><surname>Joller</surname><given-names>N</given-names></name><name><surname>Kuchroo</surname><given-names>VK</given-names></name></person-group><article-title>Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation</article-title><source>Immunity.</source><year>2016</year><volume>44</volume><fpage>989</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.05.001</pub-id><pub-id pub-id-type="pmid">27192565</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanietsky</surname><given-names>N</given-names></name><name><surname>Simic</surname><given-names>H</given-names></name><name><surname>Arapovic</surname><given-names>J</given-names></name><name><surname>Toporik</surname><given-names>A</given-names></name><name><surname>Levy</surname><given-names>O</given-names></name><name><surname>Novik</surname><given-names>A</given-names></name><etal/></person-group><article-title>The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><volume>106</volume><fpage>17858</fpage><lpage>17863</lpage><pub-id pub-id-type="doi">10.1073/pnas.0903474106</pub-id><pub-id pub-id-type="pmid">19815499</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dougall</surname><given-names>WC</given-names></name><name><surname>Kurtulus</surname><given-names>S</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Anderson</surname><given-names>AC</given-names></name></person-group><article-title>TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy</article-title><source>Immunol Rev</source><year>2017</year><volume>276</volume><fpage>112</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1111/imr.12518</pub-id><pub-id pub-id-type="pmid">28258695</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Mercier</surname><given-names>I</given-names></name><name><surname>Lines</surname><given-names>JL</given-names></name><name><surname>Noelle</surname><given-names>RJ</given-names></name></person-group><article-title>Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators</article-title><source>Front Immunol</source><year>2015</year><volume>6</volume><fpage>418</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2015.00418</pub-id><pub-id pub-id-type="pmid">26347741</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lozano</surname><given-names>E</given-names></name><name><surname>Dominguez-Villar</surname><given-names>M</given-names></name><name><surname>Kuchroo</surname><given-names>V</given-names></name><name><surname>Hafler</surname><given-names>DA</given-names></name></person-group><article-title>The TIGIT/CD226 axis regulates human T cell function</article-title><source>J Immunol</source><year>2012</year><volume>188</volume><fpage>3869</fpage><lpage>3875</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1103627</pub-id><pub-id pub-id-type="pmid">22427644</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanietsky</surname><given-names>N</given-names></name><name><surname>Rovis</surname><given-names>TL</given-names></name><name><surname>Glasner</surname><given-names>A</given-names></name><name><surname>Seidel</surname><given-names>E</given-names></name><name><surname>Tsukerman</surname><given-names>P</given-names></name><name><surname>Yamin</surname><given-names>R</given-names></name><etal/></person-group><article-title>Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR</article-title><source>Eur J Immunol</source><year>2013</year><volume>43</volume><fpage>2138</fpage><lpage>2150</lpage><pub-id pub-id-type="doi">10.1002/eji.201243072</pub-id><pub-id pub-id-type="pmid">23677581</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Ge</surname><given-names>B</given-names></name><etal/></person-group><article-title>Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells</article-title><source>Cell Death Differ</source><year>2013</year><volume>20</volume><fpage>456</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1038/cdd.2012.141</pub-id><pub-id pub-id-type="pmid">23154388</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Xia</surname><given-names>P</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-gamma production of natural killer cells via beta-arrestin 2-mediated negative signaling</article-title><source>J Biol Chem</source><year>2014</year><volume>289</volume><fpage>17647</fpage><lpage>17657</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.572420</pub-id><pub-id pub-id-type="pmid">24817116</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurtulus</surname><given-names>S</given-names></name><name><surname>Sakuishi</surname><given-names>K</given-names></name><name><surname>Ngiow</surname><given-names>SF</given-names></name><name><surname>Joller</surname><given-names>N</given-names></name><name><surname>Tan</surname><given-names>DJ</given-names></name><name><surname>Teng</surname><given-names>MW</given-names></name><etal/></person-group><article-title>TIGIT predominantly regulates the immune response via regulatory T cells</article-title><source>J Clin Invest</source><year>2015</year><volume>125</volume><fpage>4053</fpage><lpage>4062</lpage><pub-id pub-id-type="doi">10.1172/JCI81187</pub-id><pub-id pub-id-type="pmid">26413872</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gur</surname><given-names>C</given-names></name><name><surname>Ibrahim</surname><given-names>Y</given-names></name><name><surname>Isaacson</surname><given-names>B</given-names></name><name><surname>Yamin</surname><given-names>R</given-names></name><name><surname>Abed</surname><given-names>J</given-names></name><name><surname>Gamliel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Binding of the Fap2 protein of fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack</article-title><source>Immunity.</source><year>2015</year><volume>42</volume><fpage>344</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.01.010</pub-id><pub-id pub-id-type="pmid">25680274</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joller</surname><given-names>N</given-names></name><name><surname>Hafler</surname><given-names>JP</given-names></name><name><surname>Brynedal</surname><given-names>B</given-names></name><name><surname>Kassam</surname><given-names>N</given-names></name><name><surname>Spoerl</surname><given-names>S</given-names></name><name><surname>Levin</surname><given-names>SD</given-names></name><etal/></person-group><article-title>Cutting edge: TIGIT has T cell-intrinsic inhibitory functions</article-title><source>J Immunol</source><year>2011</year><volume>186</volume><fpage>1338</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1003081</pub-id><pub-id pub-id-type="pmid">21199897</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>RJ</given-names></name><name><surname>Comps-Agrar</surname><given-names>L</given-names></name><name><surname>Hackney</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Huseni</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function</article-title><source>Cancer Cell</source><year>2014</year><volume>26</volume><fpage>923</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2014.10.018</pub-id><pub-id pub-id-type="pmid">25465800</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Bi</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity</article-title><source>Nat Immunol</source><year>2018</year><volume>19</volume><fpage>723</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0132-0</pub-id><pub-id pub-id-type="pmid">29915296</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>BL</given-names></name><name><surname>Garrido-Laguna</surname><given-names>I</given-names></name></person-group><article-title>TIGIT: a novel immunotherapy target moving from bench to bedside</article-title><source>Cancer Immunol Immunother</source><year>2018</year><volume>67</volume><fpage>1659</fpage><lpage>1667</lpage><pub-id pub-id-type="doi">10.1007/s00262-018-2246-5</pub-id><pub-id pub-id-type="pmid">30232519</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><mixed-citation publication-type="other">SITC18: Merck highlights new LAG-3 and TIGIT data. <ext-link ext-link-type="uri" xlink:href="https://www.fiercebiotech.com/biotech/sitc-merck-highlights-new-lag-3-and-tigit-data">https://www.fiercebiotech.com/biotech/sitc-merck-highlights-new-lag-3-and-tigit-data</ext-link>. Accessed 21 Sept 2019.</mixed-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceeraz</surname><given-names>S</given-names></name><name><surname>Nowak</surname><given-names>EC</given-names></name><name><surname>Noelle</surname><given-names>RJ</given-names></name></person-group><article-title>B7 family checkpoint regulators in immune regulation and disease</article-title><source>Trends Immunol</source><year>2013</year><volume>34</volume><fpage>556</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/j.it.2013.07.003</pub-id><pub-id pub-id-type="pmid">23954143</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lines</surname><given-names>JL</given-names></name><name><surname>Pantazi</surname><given-names>E</given-names></name><name><surname>Mak</surname><given-names>J</given-names></name><name><surname>Sempere</surname><given-names>LF</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>O'Connell</surname><given-names>S</given-names></name><etal/></person-group><article-title>VISTA is an immune checkpoint molecule for human T cells</article-title><source>Cancer Res</source><year>2014</year><volume>74</volume><fpage>1924</fpage><lpage>1932</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-1504</pub-id><pub-id pub-id-type="pmid">24691993</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flies</surname><given-names>DB</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Cutting edge: a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models</article-title><source>J Immunol</source><year>2011</year><volume>187</volume><fpage>1537</fpage><lpage>1541</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1100660</pub-id><pub-id pub-id-type="pmid">21768399</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowak</surname><given-names>EC</given-names></name><name><surname>Lines</surname><given-names>JL</given-names></name><name><surname>Varn</surname><given-names>FS</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Sarde</surname><given-names>A</given-names></name><name><surname>Mabaera</surname><given-names>R</given-names></name><etal/></person-group><article-title>Immunoregulatory functions of VISTA</article-title><source>Immunol Rev</source><year>2017</year><volume>276</volume><fpage>66</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1111/imr.12525</pub-id><pub-id pub-id-type="pmid">28258694</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JH</given-names></name><name><surname>Wu</surname><given-names>GP</given-names></name><name><surname>Manick</surname><given-names>B</given-names></name><name><surname>Hernandez</surname><given-names>V</given-names></name><name><surname>Renelt</surname><given-names>M</given-names></name><name><surname>Erickson</surname><given-names>C</given-names></name><etal/></person-group><article-title>VSIG-3 as a ligand of VISTA inhibits human T-cell function</article-title><source>Immunology.</source><year>2019</year><volume>156</volume><fpage>74</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1111/imm.13001</pub-id><pub-id pub-id-type="pmid">30220083</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Mercier</surname><given-names>I</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Lines</surname><given-names>JL</given-names></name><name><surname>Day</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Sergent</surname><given-names>P</given-names></name><etal/></person-group><article-title>VISTA regulates the development of protective antitumor immunity</article-title><source>Cancer Res</source><year>2014</year><volume>74</volume><fpage>1933</fpage><lpage>1944</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-1506</pub-id><pub-id pub-id-type="pmid">24691994</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dempke</surname><given-names>WCM</given-names></name><name><surname>Fenchel</surname><given-names>K</given-names></name><name><surname>Uciechowski</surname><given-names>P</given-names></name><name><surname>Dale</surname><given-names>SP</given-names></name></person-group><article-title>Second- and third-generation drugs for immuno-oncology treatment-the more the better?</article-title><source>Eur Cancer (Oxford, England : 1990)</source><year>2017</year><volume>74</volume><fpage>55</fpage><lpage>72</lpage></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blando</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Higa</surname><given-names>MG</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Vence</surname><given-names>L</given-names></name><name><surname>Yadav</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer</article-title><source>Proc Natl Acad Sci U S A</source><year>2019</year><volume>116</volume><fpage>1692</fpage><lpage>1697</lpage><pub-id pub-id-type="doi">10.1073/pnas.1811067116</pub-id><pub-id pub-id-type="pmid">30635425</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>DV</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Duong</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Murine B7-H3 is a negative regulator of T cells</article-title><source>J Immunol</source><year>2004</year><volume>173</volume><fpage>2500</fpage><lpage>2506</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.173.4.2500</pub-id><pub-id pub-id-type="pmid">15294965</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suh</surname><given-names>WK</given-names></name><name><surname>Gajewska</surname><given-names>BU</given-names></name><name><surname>Okada</surname><given-names>H</given-names></name><name><surname>Gronski</surname><given-names>MA</given-names></name><name><surname>Bertram</surname><given-names>EM</given-names></name><name><surname>Dawicki</surname><given-names>W</given-names></name><etal/></person-group><article-title>The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses</article-title><source>Nat Immunol</source><year>2003</year><volume>4</volume><fpage>899</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1038/ni967</pub-id><pub-id pub-id-type="pmid">12925852</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janakiram</surname><given-names>M</given-names></name><name><surname>Shah</surname><given-names>UA</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>A</given-names></name><name><surname>Schoenberg</surname><given-names>MP</given-names></name><name><surname>Zang</surname><given-names>X</given-names></name></person-group><article-title>The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3</article-title><source>Immunol Rev</source><year>2017</year><volume>276</volume><fpage>26</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1111/imr.12521</pub-id><pub-id pub-id-type="pmid">28258693</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castellanos</surname><given-names>JR</given-names></name><name><surname>Purvis</surname><given-names>IJ</given-names></name><name><surname>Labak</surname><given-names>CM</given-names></name><name><surname>Guda</surname><given-names>MR</given-names></name><name><surname>Tsung</surname><given-names>AJ</given-names></name><name><surname>Velpula</surname><given-names>KK</given-names></name><etal/></person-group><article-title>B7-H3 role in the immune landscape of cancer</article-title><source>Am J Clin Exp Immunol</source><year>2017</year><volume>6</volume><fpage>66</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">28695059</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benzon</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>SG</given-names></name><name><surname>Haffner</surname><given-names>MC</given-names></name><name><surname>Takhar</surname><given-names>M</given-names></name><name><surname>Erho</surname><given-names>N</given-names></name><name><surname>Yousefi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis</article-title><source>Prostate Cancer Prostatic Dis</source><year>2017</year><volume>20</volume><fpage>28</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1038/pcan.2016.49</pub-id><pub-id pub-id-type="pmid">27801901</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Goldgur</surname><given-names>Y</given-names></name><name><surname>Cheal</surname><given-names>SM</given-names></name><name><surname>Guo</surname><given-names>HF</given-names></name><etal/></person-group><article-title>Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3</article-title><source>J Biol Chem</source><year>2015</year><volume>290</volume><fpage>30018</fpage><lpage>30029</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.679852</pub-id><pub-id pub-id-type="pmid">26487718</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>K</given-names></name><name><surname>Kushner</surname><given-names>BH</given-names></name><name><surname>Modak</surname><given-names>S</given-names></name><name><surname>Pandit-Taskar</surname><given-names>N</given-names></name><name><surname>Smith-Jones</surname><given-names>P</given-names></name><name><surname>Zanzonico</surname><given-names>P</given-names></name><etal/></person-group><article-title>Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma</article-title><source>J Neurooncol</source><year>2010</year><volume>97</volume><fpage>409</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1007/s11060-009-0038-7</pub-id><pub-id pub-id-type="pmid">19890606</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souweidane</surname><given-names>MM</given-names></name><name><surname>Kramer</surname><given-names>K</given-names></name><name><surname>Pandit-Taskar</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Haque</surname><given-names>S</given-names></name><name><surname>Zanzonico</surname><given-names>P</given-names></name><etal/></person-group><article-title>Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-Centre, dose-escalation, phase 1 trial</article-title><source>Lancet Oncol</source><year>2018</year><volume>19</volume><fpage>1040</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(18)30322-X</pub-id><pub-id pub-id-type="pmid">29914796</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gavrieli</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>N</given-names></name><name><surname>Loftin</surname><given-names>SK</given-names></name><name><surname>Murphy</surname><given-names>TL</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name></person-group><article-title>Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2</article-title><source>Biochem Biophys Res Commun</source><year>2003</year><volume>312</volume><fpage>1236</fpage><lpage>1243</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2003.11.070</pub-id><pub-id pub-id-type="pmid">14652006</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>P</given-names></name><name><surname>Goularte</surname><given-names>OD</given-names></name><name><surname>Rufner</surname><given-names>K</given-names></name><name><surname>Wilkinson</surname><given-names>B</given-names></name><name><surname>Kaye</surname><given-names>J</given-names></name></person-group><article-title>An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection</article-title><source>J Immunol</source><year>2004</year><volume>172</volume><fpage>5931</fpage><lpage>5939</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.10.5931</pub-id><pub-id pub-id-type="pmid">15128774</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sedy</surname><given-names>JR</given-names></name><name><surname>Gavrieli</surname><given-names>M</given-names></name><name><surname>Potter</surname><given-names>KG</given-names></name><name><surname>Hurchla</surname><given-names>MA</given-names></name><name><surname>Lindsley</surname><given-names>RC</given-names></name><name><surname>Hildner</surname><given-names>K</given-names></name><etal/></person-group><article-title>B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator</article-title><source>Nat Immunol</source><year>2005</year><volume>6</volume><fpage>90</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1038/ni1144</pub-id><pub-id pub-id-type="pmid">15568026</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>MW</given-names></name><name><surname>Cheung</surname><given-names>TC</given-names></name><name><surname>Ware</surname><given-names>CF</given-names></name></person-group><article-title>The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation</article-title><source>Immunol Rev</source><year>2011</year><volume>244</volume><fpage>169</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2011.01064.x</pub-id><pub-id pub-id-type="pmid">22017438</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>KM</given-names></name><name><surname>Nelson</surname><given-names>CA</given-names></name><name><surname>Sedy</surname><given-names>JR</given-names></name></person-group><article-title>Balancing co-stimulation and inhibition with BTLA and HVEM</article-title><source>Nat Rev Immunol</source><year>2006</year><volume>6</volume><fpage>671</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1038/nri1917</pub-id><pub-id pub-id-type="pmid">16932752</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>G</given-names></name><name><surname>Anumanthan</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>JA</given-names></name><name><surname>Greenfield</surname><given-names>EA</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name></person-group><article-title>CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator</article-title><source>Nat Immunol</source><year>2008</year><volume>9</volume><fpage>176</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1038/ni1554</pub-id><pub-id pub-id-type="pmid">18193050</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><mixed-citation publication-type="other">IND for Junshi Biosciences' FIH anti-BTLA antibody approved by FDA<bold>.</bold><ext-link ext-link-type="uri" xlink:href="http://www.junshipharma.com/upload/201904/26/201904260917018006.pdf">http://www.junshipharma.com/upload/201904/26/201904260917018006.pdf</ext-link>. Accessed 21 Sept 2019.</mixed-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>JW</given-names></name><name><surname>Liu</surname><given-names>LN</given-names></name><name><surname>Flies</surname><given-names>DB</given-names></name><name><surname>Nie</surname><given-names>XX</given-names></name><name><surname>Toki</surname><given-names>M</given-names></name><etal/></person-group><article-title>Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy</article-title><source>Nat Med</source><year>2019</year><volume>25</volume><fpage>656</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0374-x</pub-id><pub-id pub-id-type="pmid">30833750</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>G</given-names></name><name><surname>Xiao</surname><given-names>Z</given-names></name><name><surname>Yin</surname><given-names>Z</given-names></name></person-group><article-title>Normalization cancer immunotherapy: blocking Siglec-15!</article-title><source>Signal Transduct Target Ther</source><year>2019</year><volume>4</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1038/s41392-019-0045-x</pub-id><pub-id pub-id-type="pmid">31016034</pub-id></element-citation></ref></ref-list></back></article>